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Abstract:  
      MicroRNAs (miRNAs) are small non-coding RNAs that can repress protein synthesis 
by translational repression and mRNA decay to regulate signaling pathways. miRNAs 
play important roles in various cellular processes including cell inflammatory response 
and differentiation. 
        NF-κB is one of the best-characterized transcription factors providing the link 
between early membrane-proximal signaling events and changes in gene expression, and 
regulates the expression of many genes that play a role in inflammation. Here, we 
evaluated the in vitro effect of lipopolysaccharide (LPS) on cultured bovine alveolar 
macrophages and report that miR-26b, a LPS - responsive miRNA, repressed the 
phosphatase and tensin homolog (PTEN) involved in the activation of the NF-κB 
signaling pathway in bovine alveolar macrophages. LPS stimulation up-regulated miR-
26b after 1 h and down-regulated miR-26b after 6 and 36 h. Furthermore, miR-26b 
enhanced the LPS-induced TNF-α, IL-8, IL-1β, IL-10 and nitric oxide production and 
directly inhibited that of IL-6. In addition, miR-26b promoted LPS-induced NF-B 
signaling pathway. Moreover, miR-26b directly leads to PTEN silencing in bovine 
alveolar macrophages. PTEN silencing enhanced the LPS-induced mRNA expression of 
TNF-α, IL-8, IL-1β, IL-10 and IL-6, and up-regulated the NF-κB pathway. Taken 
together, we conclude that miR-26b participates in the inflammatory response of LPS- 
stimulated bovine alveolar macrophages by modulating the NF-κB pathway through 
targeting PTEN. 
        The efficacy of the current protocols to differentiate mouse induced pluripotent stem 
cells (iPSCs) and Mesenchymal Stem Cells (MSCs) into alveolar epithelial type II (AEC 
II) cells is low. And, whether miRNAs are involved in the differentiation of iPSCs and 
MSCs into lung epithelial cells is unknown. We aimed to identify specific miRNAs that 
can efficiently promote the differentiation of iPSCs and MSC into AEC II cells. Through 
miRNA microarray analysis, we identified that miR-29a was highly enriched in AEC II 
cells. miR-29a induced the differentiation of iPSCs and MSCs into AEC II cells under the 
stimulation of proper growth factors and growing on appropriate matrix. We show here 
that miR-29a suppressed the Dual-Specificity Phosphatase 2 (DUSP2) involved in the 
activation of the mitogen-activated protein kinase (MAPK) signaling pathway to promote 
the differentiation of iPSCs and MSCs into AEC II cells. In addition, dexamethasone, 8-
bromoadenosine 3, 5-cyclic monophosphate (cAMP), and isobutylmethylxanthine 
(IBMX) (DCI) further facilitated the miR-29a-mediated differentiation process. 
Moreover, we found that AEC II cells derived from iPSCs and MSCs secreted pulmonary 
surfactant and trans-differentiated into alveolar epithelial type I (AEC I) cells. 
Furthermore, miR-29a engineered MSC-AEC II cells attenuated lung injury induced by 
elastase. In addition, our studies may contribute to the cell-based therapy for COPD. 
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I-1:  MicroRNAs 
      MiRNAs are a class of evolutionarily conserved small non-coding RNAs (~21–23 
nucleotides) (1, 2). miRNAs regulate the target gene expression at post-transcriptional level by 
imperfect base pairing specifity between sequences in the 3′-untranslated region (3′-UTR), and 
the miRNA 5′-proximal ‘seed’ region (positions 2–8) (3, 4). The interaction between miRNA and 
its mRNA target typically leads to protein synthesis inhibition by translational repression and 
mRNA decay (5). In rare cases, miRNAs can activate translation (6, 7).  miRNAs have important 
roles in various critical cellular processes such as apoptosis, proliferation, and differentiation (8-
10).  
       It is also known that miRNAs are potential regulators to immune responses in immunoactive 
cells including alveolar macrophage cells (11).
 
Numerous investigations have supported that 
miRNAs are new regulators of inflammatory and immune responses (12, 13). NF-B pathway 
plays an important role in inflammatory and immune responses. While it has been reported that 
miR-146 is an NF-B transactivational target and is involved in a negative feedback loop by 
down regulation of IRAK1 and TRAF6 (14). miR-155 has also been indicated to be an NF-B 
transactivational target and negatively regulates IKKs and other genes, constituting a negative 
feedback loop (14). miR-181b works as a key player in a positive feedback loop linking NF-B 
(NF-B - IL-6 - STAT3 - miR-181b-CYLD-NF-B) and promotes cell transformation through 
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participating in an exclusive epigenetic circuit (14). Unlike miR-181b, miR-21 has recently been 
identified to be involved in the inflammation-transformation positive feedback loop to elevate 
NF-B activity through repressing PTEN expression (14). miR-301a increases NF-B activity 
down-regulating NKRF, which in turn, promotes miR-301a transcription (14). Collectively, all 
these data strongly suggest that miRNAs play an important role as central regulators of the NF-
B pathway. However, currently, the target genes and the biological function of miRNAs in NF-
B pathway of bovine alveolar macrophages (bAMs) related to bovine lung disease is still poorly 
characterized. 
       MiRNAs have been used to generate iPSCs from fibroblast and the miR-302 / 367 cluster has 
been reported to reprogram mouse and human somatic cells to iPSCs without exogenous 
transcription factors (15) . Down-regulation of miR-21 and miR-29a enhances embryonic 
fibroblasts (MEFs) reprogramming efficiency into iPSCs through ERK1/2 phosphorylation (16). 
In another study, miR-130, miR-301 and miR-721 were shown to enhance iPSC generation via 
targeting the homeobox transcription factor Meox2 (also known as Gax) (17). Thus, it is 
reasonable to speculate that certain miRNAs may increase the efficiency of differentiation of 
iPSCs into lung epithelial cells based on the modulation and fine-tuning of transcriptional 
networks under proper conditions. However, few studies have been made on miRNAs and 
differentiation of iPSCs into AEC II in vitro. 
       MiRNAs have been identified to act in functional networks linked to MSC differentiation as 
well. MiR-29a has been reported to suppress FOXA3A and to decrease chondrogenic 
differentiation from human MSCs (18). MiR-128, which is enriched in brain, has been found to 
regulate rat bone marrow MSC differentiation into neuron-like cells through Wnt signaling (19) 
MiR-204 has been determined to target RUNX2 and promotes adipocyte differentiation from 
human MSCs (20) Recently, human decidua-derived MSCs have been reported to be able to 
differentiate into functional AEC II cells that synthesize and secrete pulmonary surfactant 
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complex (21) However, the role of miRNAs in regulating MSC differentiation into AEC II cells 
is not well understood. The focus of this study is to highlight the regulation of AEC II 
differentiation from MSCs by miRNA. 
I-2: Bovine Respiratory Disease (BRD) 
       Bovine respiratory disease (BRD) complex, also known as shipping fever, is one of the 
biggest health obstacles and causes great economic losses in the global cattle industry (22). 
Stressful management practices, environmental factors, and a variety of microorganisms are 
believed to contribute to the pathogenesis of BRD. Mannheimia haemolytica, formally known as 
Pasteurella haemolytica, is a small gram-negative, facultatively anaerobic bacterium and is the 
primary bacterial agent responsible for the clinical disease and pathophysiological events 
characterized by acute lobar fibrinonecrotizing pneumonia (23). M. haemolytica alone can cause 
fibrinous pneumonia when directly delivered into the lungs in sufficient numbers (>5 X10
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colony-forming units in non-immune calves) (24). M. haemolytica produces various potential 
virulence factors. One of them is the endotoxin, lipopolysaccharide (LPS) that causes acute 
inflammation, hemorrhage, edema and hypoxemia (25).  
       Among these main products of M. haemolytica, LPS is one of the toxins involved in BRD 
complex. LPS is a component of the outer membrane of Gram-negative bacteria such as M. 
haemolytica and Escherichia coli which stimulates the innate immune system and is one of the 
most important pathological initiating factors during severe bovine inflammatory disease (26). M. 
haemolytica LPS is a well-characterized virulence factor because of its pathogenic role in 
shipping fever (27, 28).  In addition, LPS stimulation of macrophages enhances acetylation of 
histone H4 lysine residues that are believed to be responsible for neutrophil recruitment (29). The 
inflammatory response which is associated with lung injury due to bacterial infection is an 
important aspect of BRD. It has been demonstrated that LPS from E.coli (O55: B5) causes the 
intensive enzymatic and oxidative response of bovine neutrophils in vitro during the course of 
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BRD (26). The ensuing inflammatory response to LPS and the associated lung injury and sepsis 
are pivotal in BRD (26). However, the pathogenesis of BRD is still not completely understood. 
I-3: Chronic Obstructive Pulmonary Disease (COPD) 
        Chronic obstructive pulmonary disease (COPD) is a worldwide health problem and a major 
cause of chronic morbidity and mortality throughout the world.  COPD is predicted to become the 
third leading cause of death by 2030. The causes of COPD are cigarette smoking, indoor air 
pollution (such as biomass fuel used for cooking and heating), outdoor air pollution, occupational 
dusts and chemicals (vapors, irritants, and fumes) or alpha1-antitrypsin deficiency. Cigarette 
smoking is the major risk factor.  To attenuate and eventually limit this increasing COPD trend, a 
unified international effort is required. 
       COPD is characterized by progressive and chronic inflammation of the lungs, breathlessness, 
and fatigue and reduced daily activity. These symptoms worsen acutely at exacerbations of 
chronic bronchitis. The airflow limitation in COPD that is associated with chronic inflammation 
is also progressive and not fully reversible. Patients who have symptoms of cough, sputum 
production, or dyspnea, and / or a history of exposure to risk factors for COPD should be 
considered for a diagnosis of COPD.  The presence of FEV1< 80% and a combination of FEV1/ 
FVC<70% indicates that it is not fully reversible of the airflow limitation. 
      The central airways, peripheral airways and pulmonary vasculature all have pathologic 
changes in COPD. Inflammatory cells infiltrate the surface epithelium of trachea, bronchi, and 
bronchioles with internal diameter greater than 2 to 4 mm (30-32). Mucus hyper secretion leads to 
enlarged mucus-secreting glands and increasing numbers of goblet cells. For small bronchi and 
bronchioles with an internal diameter of less than 2 mm, chronic inflammation results in repeat 
cycles of airway wall injury and repair (33) that causes airway wall structural remodeling. In 
those remodeled airways, collagen content and scar tissue that narrows the lumen increase (34). 
Eventually, fixed airway obstruction is produced(34) . 
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       Pulmonary vasculature also changes in COPD.  It is characterized by thickening of the vessel 
walls in the beginning of COPD. Intimal thickening occursin the beginning followed by 
increasing smooth muscle proliferation and inflammatory cell infiltration of the vessel wall (35, 
36). As COPD worsens, mucus hypersecretion, ciliary dysfunction, airflow limitation, pulmonary 
hyperinflation, gas exchange abnormalities, pulmonary hypertension and cor pulmonale will 
develop. These will lead to symptoms including chronic cough, sputum production, and 
destruction of alveolar structure. In advanced COPD, the lung’s capacity for gas exchange 
decreases due to peripheral airway obstruction, parenchymal destruction, and pulmonary vascular 
abnormalities, producing hypoxemia and hypercapnia. Cardiovascular complications of COPD 
develop as well, such as high blood pressure (37). 
        Lung transplantation is a possible treatment for patients who have end stage lung diseases 
including chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, cystic fibrosis, 
alpha1-antitrypsin disease, and primary pulmonary hypertension. However, it is limited because 
of the low availability of donor lungs, immune rejection and complications. Due to these 
limitations, lung stem and progenitor cells or alveolar cell transplantation is an attractive 
alternative therapy (38). However, the limitation of this approach is the scarcity of alveolar 
epithelial cells and the difficulty of expanding these cells in vitro. One potential future treatment 
for severe lung diseases including COPD is to find a reliable source of functional lung epithelial 
cells for use in lung-related therapies. Induced pluripotent stem cells (iPSC) and adult 
mesenchymal stem cells (MSC) are two possible cell sources for cell-based treatments. 
I-4: Stem Cells 
      Stem cells are cells in the body that share 3 main characteristics including unlimited self-
renew through cell division, differentiation to form different structures and tissues as the need 
arises, and continual division and differentiation after they are transplanted into another organism.  
In general, stem cells are a continual source of cells throughout the individual life-span.  
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       Stem cells are typically classified into embryonic stem cells and adult stem cells. Embryonic 
stem cells are derived from the inner mass of the blastocyst. Embryonic stem cells are referred to 
as totipotent since they are able to regenerate all three germ layers of an organism. Adult stem 
cells that are able to differentiate to one or several mature cells types are considered uni- or 
multipotent (39, 40). 
        Stem cell-based therapy has successfully demonstrated beneficial therapeutic effects in a 
variety of diseases including heart disease, bone disease, cancer, hepatic disease, and lung disease 
(41-45). In recent years, there is increasing interest in exploiting the potential therapeutic 
properties of stem cells for the treatment of lung diseases, and stem cells have been extensively 
investigated as a potential source of alveolar epithelial cells (21). It has been reported that stem 
cells have therapeutic effects on COPD characterized by emphysema and chronic bronchitis (46-
48). 
       iPSCs are embryonic-like cells reprogrammed from mouse and human adult somatic cells 
through retroviral transduction of defined factors, and possess various properties of embryonic 
stem cells(49). Thus, iPSCs offer the possibility to generate gene-corrected and patient-specific 
lung progenitor cells for individuals with genetic diseases (50). iPSCs became one of the most 
promising applications for patient-specific regenerative medicine due to their self-renewal 
capacity and potential for differentiation (51). Current clinical strategies are not effective for 
progressive chronic lung disease. Therefore, cell-based therapies have become an important new 
frontier in lung research and disease treatment (52). Particularly, for these lung diseases caused 
by developmental deficiencies or chronic depletion of endogenous stem cell pools such as COPD, 
exogenous stem cell therapies may represent a better approach (53). Recent studies have reported 
that mesenchymal stem cells (MSCs) and endothelial progenitor cells (EPCs) are candidates for 
cell therapy of COPD (49, 54, 55). Currently, investigations have begun to examine the 
possibility of generating lung progenitor epithelial cells from somatic cells since iPSCs can be 
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created from dermal skin fibroblasts and patient specific iPSCs could avoid the immune rejection 
problems that might occur if heterologous sources of embryonic stem cells were employed (50). 
Deciphering the regulation mechanisms of efficient differentiation to target cells would unveil the 
pathophysiology of diseases and provide a potential therapeutic strategy for specific diseases (56, 
57). There is increasing interest in exploiting the regenerative potential of stem cells or progenitor 
cells for the treatment of chronic lung diseases like COPD. Cell transplantation becomes an 
alternative to whole – organ transplantation (38). However, this approach requires generating 
large quantities of pure AEC II cells in vitro and conditions for directing iPSCs to differentiate 
along an alveolar epithelial lineage with homogeneity are not yet fully defined. Recent studies 
have shown that human iPSC- derived AEC II cells adhered to and proliferated within the 
acellular lung matrices of rats and humans, and displayed markers of differentiated pulmonary 
epithelium (58). Previous studies have revealed that both endothelial progenitor cells activated by 
hepatocyte growth factor (HGF) and autologous stem cells (ASCs) have benefited lung damage in 
an elastase-induced emphysema model (59, 60). Based on these findings, we sought to investigate 
the regenerative potential of miRNA engineered iPSCs – AEC II cells in the context of an 
elastase induced mouse emphysema model. 
     MSCs are cells that can be collected from mesenchyme or stroma of several tissues such as 
bone marrow and adipose tissue (61-63) and able to differentiate into derivatives of the 
mesodermal lineage including adipocytes, osteocytes, chondrocytes, and myocytes. MSCs have 
been assessed in a large number of clinical trials since MSCs are able to home to sites of injury 
and inflammation, differentiate into cells of the mesodermal lineage, and secrete trophic factors to 
promote proliferation and differentiation of local progenitor cells (64). In a recent study, bone 
marrow (BM)-derived stem cells transplanted to the lungs were shown to benefit regeneration 
after elastase-induced pulmonary emphysema (59). Another study revealed that adipose stem cell 
treatment in mice attenuated lung and systemic injury induced by cigarette smoking (65). 
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However, the effect and potential therapeutic treatment of miRNA- engineered MSCs in COPD is 
still unclear. 
I-5: Alveolar Epithelial Type II (AEC II) Cells 
          Gas exchange in the lung occurs within alveoli, alveolar epithelium, and capillaries. 
Efficient gas exchange and host defense rely on the integrity of the alveolar epithelium. The 
alveolar epithelium is composed of alveolar epithelial type I (AEC I) and type II cells (AEC II). 
AEC II cells play a vital role in maintaining alveolar homeostasis and are considered to be the 
progenitor cells of the alveolar epithelium, which are critical for lung repair after injury. AEC II 
cells secrete surfactant (66, 67) and proliferate when AEC I cells in the alveolar epithelium are 
damaged by a variety of disease conditions to renew the alveolar epithelium (68-70).  AEC II 
cells are also phagocytic, activate macrophages, and secrete soluble mediators associated with 
immune responses such as responding to signals of neighboring cells or circulating immune cells, 
migrating and spreading in response to injury (71-74). The repair capacity of endogenous lung 
epithelial progenitor cells is often insufficient and diminishes with increasing age. Incomplete 
repair of alveolar epithelium is one of the major factors leading to chronic lung diseases including 
chronic obstructive pulmonary diseases. Therefore, maintaining a sufficient supply of AEC II 
cells is of considerable practical and therapeutic interest. 
       Each alveolus contains AEC I cells and cuboidal AEC II cells secreting high levels of 
surfactant protein C (SP-C). In COPD and idiopathic pulmonary fibrosis (IPF), the delicate 
architecture of the alveoli is lost (75) . Several studies have indicated that in COPD these 
pathologies are induced in part by defects in the alveolar epithelium, increased apoptosis and 
senescence (76, 77) .       
       A recent study has shown that intratracheal instillation of AEC II cells reduces the severity of 
bleomycin-induced pulmonary fibrosis and that AEC II cells can be derived from human and 
mouse embryonic stem cells (78, 79). However, the efficacy of differentiation is very low and to 
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date, none of the studies has explored the role of miRNA in the differentiation of iPSCs and 






MATERIALS AND METHODOLOGY 
II-1: MicroRNA-26b modulates the NF-B pathway in bovine alveolar macrophages by  
          regulating PTEN 
 
i. Bovine alveolar macrophage isolation and LPS stimulation  
        Bovine lungs (Ralph’s Packing Company, Perkins, Oklahoma) were infused by gravity (30 







infused fluid was gauze-filtered. bAMs were collected by centrifugation (200 x g, 10 min at 4°C). 
After being washed twice in HBSS
-
, bAMs were resuspended in Dulbecco’s Modified Eagle’s 
medium (DMEM ) (ATCC, Manassas, VA) with 10% fetal bovine serum (FBS) (Atlanta 
Biologicals, Atlanta, GA) and seeded into 6- well cell culture plates at a density of 4 million cells 
per well. bAMs were allowed to adhere for 4 h and then stimulated with 1 μg/ml of Escherichia 
coli LPS (055:B5; Sigma-Aldrich, St Louis, MO) for 1-48 h. Viable cell counts were performed 
by trypan blue dye exclusion assay. The purity of bAMs was determined by 
immunocytochemistry with monoclonal anti-CD68 (EBM11). bAMs were maintained in DMEM 
containing 10% FBS, 100 U/ml penicillin and 100 mg/ml streptomycin.  
ii. Immunocytochemistry 
        Freshly isolated bAMs were seeded in 24-well cell culture plates and allowed to adhere for 
4h. Then cells were twice with phosphate buffered saline (PBS) (pH 7.4) and fixed with 4%  
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paraformaldehyde in PBS for 30 min, followed by permeabilization with 0.1% Triton X-100 for 
15 min and blocking with 1% bovine serum albumin (BSA) for 1 h. Cells were incubated with 
mouse monoclonal anti-CD68 (EBM11) (1:100) (Dako, Carpenteria, CA) at 4°C overnight. Cells 
were then washed and incubated with Alexa-Fluor-488-conjugated anti-(mouse IgG) secondary 
antibodies (1:500) (Bio-Rad, Hercules, CA). The negative controls were treated as described 
above except the omission of the primary antibody.  4', 6-Diamidino-2-phenylindole 
dihydrochloride (DAPI) (2.5 mg/ml) (Sigma-Aldrich, St Louis, MO) staining was performed for 
counting cells. Cells were viewed on a Nikon Eclipse TE 2000 U inverted fluorescence 
microscope or Nikon Eclipse E600 fluorescence microscope. 
iii. MicroRNA microarray printing, hybridization and data analysis  
       The microRNA microarray was in-house printed using miRCURY LNA™ ready-to-spot 
probe set 11.0 (Exiqon, Vedbaek, Denmark). Capture probes were complementary to mature 
microRNAs for all microRNAs in human, mouse, rat and their related viruses registered in 
miRBase Release Version 11.0. The in-house printed miRNA microarray used a miRCURY LNA 
oligo set that contained 317 bovine miRNAs. 
       Four hundred ng of total RNA from control (without LPS stimulation) samples from all time 
points (0, 1, 6 and 36 h) was used as a common reference control labeled with Hy3 or Hy5 and 
co-hybridized with the same amount of total RNAs of LPS stimulated cells from the 
corresponding time points labeled with the other dye, Hy5 or Hy3. Dye swaps was performed to 
eliminate the bias. The hybridized slides were scanned with ScanArray Express (PerkinElmer 
Life and Analytical Sciences, Boston, MA) and the images were analyzed with GenePix 5.0 pro 
(Axon Instruments, Union City, CA). The data were calculated, normalized, and qualified as 
described previously (80). For data analysis, the weak and bad spots were eliminated using 
RealSpot software according to the assigned QI. LOWESS normalization was performed for the 
remained spots. The miRNA signals from control and LPS samples were compared using a two-
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tailed student’s t-test, and those with a p-value of less than 0.05 were considered significantly 
different. 
iv. RNA isolation and quantitative real-time PCR 
        Total RNA was extracted from bAM cells using TRI Reagent (Molecular Research Center, 
Inc., Cincinnati, OH). Residual DNA was removed using DNA-free DNase (Ambion, Austin, 
TX). RNA was reverse-transcribed into cDNA using M-MLV reverse transcriptase (Invitrogen, 
Carslbad, CA). Quantitative RT-PCR (qRT-PCR) was performed in triplicate on an ABI 7500 
system (Applied Biosystems, Foster City, CA) using SYBR Green I detection and gene-specific 
primers (Table 1). The fluorescent signal was only detected in the amplification step for each 
cycle. A melt curve was generated to check the specificity of the amplification at the dissociation 
stage. 18S rRNA was used as an internal control. The relative amount of each mRNA relative to 
18S rRNA was calculated with the equation 2
- (CtmRNA –Ct18S)
. 
       For quantification of miRNA, 5 μg of total RNA was poly (A)-tailed using A-Plus™ Poly 
(A) Polymerase tailing kit (Epicentre Biotechnologies, Madison, WI). 1.5 μg of poly (A)-tailed 
RNA was reversed-transcribed into cDNA using oligo dT primers and M-MLV reverse 
transcriptase. qRT-PCR was performed using the target mature miRNA sequence as the forward 
PCR primer (Table 1) and a universal primer (5’- GCGAGCACAGAATTAATACGACTCAC-
3’) as the reverse primer. U6 snRNA was used as an internal control. The relative amount of each 




v. Cytokine measurement in culture medium 
        Immediately after collection, culture medium was centrifuged at 1,000 rpm for 5 min at 4°C 
to remove residual cells. The supernatant was harvested and stored at -80°C for subsequent 
analysis. Concentrations of TNF-α, IL-8, IL-1β, IL-10 and IL-6 in culture medium were assayed 
using a bovine TNF-α ELISA kit (Raybiotech, Norcross, GA); a bovine IL-8 ELISA kit 
13 
 
(MyBiosource, San Diego, CA); a bovine IL-1β ELISA kit (Thermo Scientific, Waltham, MA); a 
bovine IL-10 ELISA kit ( MyBiosource) and a bovine IL-6 ELISA kit (Thermo Scientific), 
following manufacturers' instructions. All samples were assayed in duplicate. Cytokine 
concentrations were determined by relevant standard curves and expressed as pg/ml. 
vi. Construction of lentiviral vectors 
          We constructed a lentiviral miR-26b expression vector as previously described (81). The 
lentiviral control vector (miR-con) contains a non-relevant sequence as a negative control. For 
PTEN silencing lentiviral vector, shRNA of PTEN (Table 1) was cloned into pSIH1-H1-copGFP 
Vector (System Biosciences, Mountain View, California, USA). The control shRNA vector was 
purchased from System Biosciences. The lentiviruses were generated in HEK 293T cells using 
Lenti-X HTX Packaging Mix (Clontech, Mountain View, CA), then titered and stored at -80°C 
until use. 
vii. Target gene and pathway analysis of miR-26b  
         Web-based Pictar (URL: http://pictar.mdc-berlin.de/) and TargetScan (URL: 
http://www.targetscan.org/mmu_50/) software was used to predict the pathways and targets of 
miR-26b. Commonly used algorithms give variable weight to: (i) complementarity to the miRNA 
seed region; (82) evolutionary conservation of the miRNA recognition elements (MREs); (iii) 
free energy of the miRNA-mRNA heteroduplex; and (iv) mRNA sequence features outside the 
target site. TargetScan and PicTar focus on the seed region in miRNA targeting (83, 84). 
TargetScan requires an exact match to ≥7 bases of the seed sequence (83). PicTar imposes a 
stringent free energy cutoff for imperfect matches (84). Both TargetScan and PicTar improve 
their predictions because of evolutionary conservation. Furthermore, TargetScan improves 
predictions for non-conserved sequences and adds a ‘context score’ considering features in the 
surrounding mRNA which include local A-U content and location (near either end of the 3′-UTR 
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is preferred) (85). mRNAs that have a high context score or multiple predicted MREs are more 
likely to be true targets. 
viii. Construction of 3’-UTR luciferase reporter vectors         
          We divided the three binding sites of PTEN into 2 segments for cloning due to the 
sequence length. PTEN1 contained two binding sites (43-49 and 1278-1285), and PTEN2 
contained one binding site (2618-2625).  PTEN1 and PTEN2 were PCR-amplified from bovine 
genomic DNA and cloned into the pmirGLO vector (Promega, Madison, WI) downstream of a 
firefly luciferase reporter gene using the Nhel I and Sal I restriction sites. We used over-lapping 
PCR to construct the luciferase reporters with mutant PTEN 3’-UTR of miR-26b binding sites. 
We first amplified PTEN1 or PTEN2 as two fragments with overlapping mutation sites using two 
primer sets.  The annealing two fragments were then used as a template to amplify the mutant 
PTEN1 or 2. The primer sequences are listed in Table 1.  
 










ix. Dual luciferase reporter assay 
        Raw 246.7 cells were seeded in a 96-well plate (2 x10
4
 cells / well). After being in culture 






reporter construct and 100 ng of miR-26b expression plasmid using Lipofectamine 2000 
(Invitrogen, Carlsbad, CA). The empty pmirGLO vector was used as a control. 24 h after 
transfection, cells were harvested and dual luciferase activities were measured. Data were 
normalized by dividing firefly luciferase activity by Renilla luciferase activity.  
        For the pathway activity, Raw 246.7 cells were seeded in a 96 well plate at a density of 2 
x10
4
 cells /well. After being in culture for 24 h, the cells were transfected with 50 ng of miR-26b 
and 100 ng of NF-κB pathway-luciferase-reporter construct (SABiosciences, Frederick, MD). 
miR-con was used as a control. 24 h after transfection, LPS (1 µg/ml) was added. After 18 h 
stimulation, the cells were harvested. NF-κB transcriptional activity was measured with the Dual 
Luciferase Reporter Assay System. Data were expressed as a ratio of firefly luciferase activity to 
Renilla luciferase activity.  
x. Western blotting 
        bAMs were stimulated with LPS (1 μg/ml) for 0, 1, 6 and 36 h. Controls were bAMs without 
LPS stimulation. Then, cells were lysed in in lysis buffer (Thermo Scientific, Rockford, IL). DC 
protein assay kit (Bio-Rad, Hercules, CA) was used to determine the protein concentration. 
Twenty µg of protein extracts were separated by 10% SDS-PAGE and then transferred onto 
nitrocellulose membranes. Proper transfer was ensured by staining the membrane with Ponceau S. 
Membranes were blocked overnight with 5% dried skimmed milk powder in 100 mM TBST. 
Then, the membranes were incubated at 4°C overnight with primary antibodies: anti-PTEN 
(1:500 dilution, Bioss, Woburn, MA) and anti-β actin (1:500 dilution, Sigma-Aldrich) as the 
loading control. After being washed with TBST three times, the membranes were incubated with 
horseradish peroxidase-conjugated secondary antibodies (Bio-Rad, Hercules, CA) for 1 h. Blots 
were washed again and target proteins were visualized using the enhanced chemiluminescence 
detection system. All experiments were repeated three times.  
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        For miR-26b overexpression, we infected bAMs with miR-26b lentivirus at a multiplicity of 
infection (MOI) of 50 and then stimulated the cells with LPS (1 μg/ml) for 5 - 60 min.  The 
lentivirus containing miR-con was used as a virus control (VC). At the end of incubation, the 
cells were lysed in lysis buffer (Thermo Scientific) and used for Western blotting as above. The 
membranes were incubated at 4°C overnight with primary antibodies: anti-PTEN (1:500 dilution, 
Bioss, Woburn, MA), anti-Akt (1:500 dilution, Bioss), anti-phospho-Akt (1:1000, Millipore, 
Bellerica, MA), anti-IKKb (1:1000, Cell Signaling Technologies, Beverly, MA), anti-IKKa 
(1:1000, Cell Signaling Technologies), anti-phospho-IKKa/b (1:1000, Cell Signaling 
Technologies, Beverly, MA), anti-IκBα (1:1000, Cell Signaling Technologies, Beverly, MA), 
anti-phospho-IκBα (1:1000, Cell Signaling Technologies, Beverly, MA),anti-NF-κB p65 (1:1000, 
Abcam, Cambridge, MA), anti-phospho-NF-κB p65 (1:500 dilution, Bioss), anti–GAPDH (1:500 
dilution, Sigma-Aldrich) and anti-β actin (1:500 dilution, Sigma-Aldrich). All experiments were 
repeated three times. Each target was run a separate gel to avoid the results may come from the 
previous blot antibodies. 
xi. Nitric oxide measurement 
        The level of nitric oxide production was monitored by measuring nitrite and nitrate 
concentration in the cultured medium. bAM culture media was collected and centrifuged at 4°C 
for 5 min to remove residual cells. The amount of nitric oxide in the supernatant was measured by 
mixing the medium with the same volume of Griess reagent (100 µl) in a 96- well plate. The plate 
was incubated for 15 min at room temperature and read at 570 nm by a spectrophotometer (86).  
xii. Statistics      
        For comparisons across more than 2 groups, statistical analysis was performed using one-
way ANOVA followed by Tukey's post hoc test. For comparisons of 2 groups, statistical analysis 
was performed using student t-test considering unequal variance. Statistical difference was 
accepted at p < 0.05. 
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II-2: MicroRNA-29a Efficiently Promotes the Differentiation of Mouse Induced Pluripotent 
Stem Cells and Mesenchymal Stem Cells into Alveolar Epithelial Type II Cells 
i. Culture of mouse iPSCs 
Mouse iPSCs (iPS-MEF-Ng-492B-4) (Cell Bank, RIKEN BioResource Center, Japan) 
were propagated on mouse embryo fibroblasts (MEFs) (ATCC, Manassas, VA). MEFs were 
seeded in 25 cm
2
 flasks and cultured in Dulbecco's Modified Eagle's Medium (DMEM) (ATCC) 
supplemented by 10% fetal bovine serum (FBS) (Atlanta Biologicals, Atlanta, GA), 50 U/ml 
penicillin and 50 mg/ml streptomycin (15140-163, Life Technologies,  Gaithersburg, MD). The 
cells were treated with mitomycin C (Sigma-Aldrich, St Louis, MO) at a final concentration of 8 
μg/ml and incubated at 37°C with 5% CO2 to halt cell division so that they could be used to 
condition the medium for iPSCs. After a 3-hr incubation at 37°C, mitomycin C-containing 
medium was aspirated and the cells were trypsinized. A single cell suspension (5 x 10
5
) was 
seeded on a gelatin (Sigma-Aldrich, St Louis, MO) coated 25 cm
2 
flask. The next day, MEF 
medium was removed and 5 ml of mouse iPSC medium was added. The iPSC medium consisted 
of DMEM (high glucose, without sodium pyruvate) (GIBCO), 15% FBS, 0.1 mM nonessential 
amino acids (Sigma-Aldrich), 0.1 mM 2-mercaptoethanol (Sigma-Aldrich), 1000 U/ml mouse 
LIF (Millipore, Bellerica, MA), 50 U/ml penicillin, and 50 mg/ml streptomycin. iPSCs were 
plated on the MEF feeder cells and cultured at 37
o
C, 5% CO2 and 90-95% humidity, with 
medium changed every day. Undifferentiated iPSCs were passaged every 4-5 days onto fresh 
feeder cells. 
ii. Removal of contaminating MEFs from iPSCs          
iPSC medium was discarded  and 1 ml per 25 cm
2 
flask of 0.25% trypsin-EDTA (Sigma-
Aldrich) was added. After a 5-min incubation, 5 ml of mouse iPSC medium was added to break 
up the cell clumps. The cells were transferred into a conical tube and centrifuged at 200 g for 5 




flask without gelatin coating. The cells were incubated at 37°C with 5% CO2 for 1 h.  Most MEF 
cells attached to the bottom of the flask. The supernatant containing iPSCs was collected and 
centrifuged at 200 g for 5 min to obtain the purified iPSCs. 
iii. Isolation of mouse BM-MSCs  
The femur and tibia were removed from C57BL/6 mice and the bones were kept in 
storage buffer (2% fetal bovine serum, 2% penicillin/streptomycin and PBS) on ice. After all the 
bones were collected, the bones were put in a p100 petri dish and washed with 20 ml of storage 
buffer once or twice so that hairs were washed away. The ends of bones were cut and the marrow 
was flushed thoroughly with the MSC culture medium (DMEM-high glucose without glutamine, 
15% FBS, 1x L-glutamine, 10 mM  2-mercaptoethanol, 5 mM N-acetyl cysteine, 800 µM N-tert-
butyl-alpha-phenylnitrone, 50 U/mL penicillin and 50 mg/mL streptomycin) using a 3 ml syringe 
until the bone become pale (reddish to white). After finishing all bones, the marrow was pipetted 
up and down into a single cell level. Cell suspension was centrifuged and the supernatant was 
removed. After that, 10 ml of fresh degassed culture medium was added. Cells were cultured in a 
5% O2 hypoxia chamber (Billus-Rothebery, CA) and incubated at 37°C with 5% CO2.  
When the cells reached 80% confluence, the culture medium was removed and 1 ml of 
0.25% trypsin-EDTA was added and incubated for 5 min at room temperature. Then, 5 ml MSC 
medium was added to break up the cells to a single cell suspension. After that, the CD11b 
population was depleted first, and then the CD45 population was depleted using specific 
antibodies [anti-mouse CD11b microbeads (130-049-601) and anti-mouse cd45 microbeads (130-
052-301)] as per the manufactures’ instruction (Miltenyi Biotec). After depletion, these cells were 
plated into two p100 dishes (P1) (1:2 split) with 10 ml of degassed medium and were incubated in 
a hypoxic (5% CO2, 5% O2 and 90% N2) chamber at 37°C. Once the culture reached 80-90% 
confluence, the cells were ready for use (P2). The purity of the attached MSCs was assessed by 
flow cytometry.  
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iv. Isolation of mouse primary AEC II cells 
        Mouse AEC II were isolated from male C57BL/6 mice (8-10 weeks of age) according to the 
previously reported procedure, with some modification (48, 49). Mice were anesthetized with 
ketamine (80 mg/kg of body weight) and xylazine (10 mg/kg of body weight). The abdominal 
cavity was opened, exsanguinated and cannulated with a 20-gauge luer stub adapter through the 
intratracheal route. Lungs were perfused with solution II which is prepared with 10 mM HEPES, 
pH 7.4, 0.9% NaCl, 0.1% glucose, 5 mM KCl, 1.3 mM MgSO4, 1.7 mM CaCl2, 0.1 mg/ml 
streptomycin sulfate, 0.06 mg/ml penicillin G, 3 mM Na2HPO4 and 3 mM NaH2PO4, followed by 
instilling 1 ml of the digestion cocktail which contains solution II plus dispase (500 caseinolytic 
units/ml) directly through the trachea. Three lungs were isolated, pooled into a beaker containing 
~17 ml of the digestion cocktail and incubated at 37°C for 45 minutes. After incubation, the lungs 
were chopped small. Lung tissues were further digested with the addition of DNase I (100 μg/ml) 
for 45 minutes at 37°C, with intermittent shaking. The digested lungs were filtered through 160-, 
37- and 15-μm gauge nylon mesh sequentially. The filtrate was centrifuged at 250 g for 10 
minutes. The cell pellet was resuspended in DMEM and incubated in a 100-mm-diameter Petri 
dish coated with mouse IgG (75 μg per dish) for 1 hour. The cells were spun down at 250 g for 10 
minutes and resuspended in DMEM containing 10% FBS. The yield was ~8×10
6
 cells per mouse 
and the cell viability was >95%. 
v. In vitro differentiation of iPSCs into AEC II cells 
         We used a two-step differentiation protocol (5) to drive iPSCs into AEC II cells. The first 
step was endoderm induction for 6 days in differentiation medium plus Activin A (20 ng/ml).  
The differentiation medium consisted of  25% (v/v) Ham’s F12 medium (Invitrogen, Carlsbad, 
CA), 75% (v/v) Iscove’s modified Dulbecco’s medium (Invitrogen) supplemented with 0.5X of 
N-2 Supplement and  B-27 Supplement minus vitamin A (Invitrogen), 0.05% BSA, 2 mM 
glutamine (Invitrogen), 0.5 mM ascorbic acid (Sigma), 0.45 mM 1-thioglycerol (Sigma-Aldrich ), 
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50 U/ml penicillin and 50 mg/ml streptomycin (5). The second step was lung epithelial induction 
for 5 days in differentiation medium containing FGF-2 (50 ng /ml).  Medium was changed daily. 
vi. In vitro Differentiation of MSCs into AEC II cells  
         
        1 x 10
5
 P2 MSCs were seeded on each well of collagen IV-coated 6-well plates and cultured 
in differentiation medium (small airway growth medium, SAGM) and MSC culture medium 
(Control) for 11 days. SAGM media is a previously established lung differentiation culture media 
(87-89). 
         For miR-29a derived MSC differentiation, MSCs were infected with miR-29a lentivirus at a 
MOI of 50. After culture for 24h, cells were serum starved for another 24h. Then, media wwas 
switched to SAGM with DCI and cells were cultured for 11 days.  
vii. Immunocytochemistry 
         iPSCs were plated onto gelatin-coated 24-well cell tissue culture plates at a density of 1 x 
10
6
 cells per well. Immunostaining was carried out the next day. Cells were washed with 
phosphate-buffered saline (PBS), fixed with 4% paraformaldehyde in PBS for 30 min at room 
temperature, and permeabilized with 0.1% Triton X-100 for 15 min. The fixed cells were blocked 
with 1% bovine serum albumin (BSA) for 1 h and were then incubated with mouse monoclonal 
anti-Nanog (1:100, Sigma-Aldrich) or anit-SSEA-1 (1:100, Life Technology) at 4°C overnight. 
The cells were washed and incubated with Alexa-Fluor-488-conjugated anti-mouse IgG 
secondary antibodies (1:500) (Bio-Rad, Hercules, CA).  4', 6-Diamidino-2-phenylindole 
dihydrochloride (DAPI) (2.5 mg/ml) (Sigma-Aldrich) nuclear staining was performed for 
counting cells. 
         iPSC or MSC differentiated cells were plated onto 24-well cell tissue culture plates at a 
concentration of 1 x 10
6
 cells per well. Immunostaining was carried out the next day. Cells were 
washed with PBS, fixed with 4% paraformaldehyde in PBS for 30 min at room temperature (RT) 
and permeabilized with 0.1% Triton X-100 for 15 min at RT. Cells were blocked with 1% bovine 
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serum albumin (BSA) for 1 h at RT. Cells were incubated with mouse monoclonal anti-SP-C 
(1:100, Santa Cruz Biotechnology, CA) or syrian hamster anti-T1 α (1:100, Developmental 
Studies Hybridoma Bank, Iowa City, IA) at 4°C overnight. The next day, cells were washed and 
incubated with Alexa-Fluor-546-conjugated anti-mouse IgG secondary antibodies (1:500) 
(Biolegend, San Diego, CA) or Alexa-Fluor-546-conjugated goat anti-hamster IgG secondary 
antibody (Life Technology). 4', 6-Diamidino-2-phenylindole dihydrochloride (DAPI) (2.5 mg/ml) 
(Sigma-Aldrich, St Louis, MO) nuclear staining was performed for counting cells.        
           Cells were viewed on a Nikon Eclipse TE 2000 U inverted fluorescence microscope or 
Nikon Eclipse E600 fluorescence microscope. 
 viii. Flow cytometry analysis of mesenchymal stem cell surface molecules 
         Mouse bone marrow MSCs were assessed by flow cytometry before and after 
differentiation. Cells were dissociated into a single-cell suspension by incubation with 0.25% 
trypsin-EDTA for 2 min at room temperature. Cells were then washed and resuspended in PBS 
containing 1% BSA at a density of 50,000 cells in 100 µl for each marker. Rat anti-mouse 
CD16/CD32 (#553141, BD Biosciences, San Jose, CA) was added first to block non-antigen-
specific binding sites of immunoglobulins to Fc-receptors. Then, cells were washed, resuspended 
with PBS containg1% BSA (Fisher) and incubated on ice for 30 min in the dark with 1 µl 
conjugated antibodies against Sca-1 (eBioscience, San Diego, CA), CD9 ( eBioscience), CD29 
(eBioscience), CD44 (eBioscience), CD81 (eBioscience), CD11B ( eBioscience), CD45 
(eBioscience). In a parallel group, cells were also incubated on ice for 30 min in the dark with 1 
µl related IgG including rat IgG2a K Isotype Control Alexa Fluor 488 (eBioscience), rat IgG2b K 
Isotype Control Alexa Fluor 488 (eBioscience), Armenian Hamster IgG Isotype Control PE 
(eBioscience), Mouse IgG1 K Isotype Control PE (eBioscience), anti-Mouse CD31 (PECAM-1) 
PE (eBioscience) and streptavidin PerCP-Cyanine5.5 (eBioscience). For CD81 which needed a 
secondary antibody for detection, cells were resuspended in 100 µl of PBS containing 1% BSA 
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with 1 µl streptavidin PerCP-Cyanine5.5 (eBioscience) for another 30 min on ice in the dark after 
the primary antibody was washed away. The control group was unstained cells. Cells were 
washed twice with PBS containing 1% BSA and analyzed by flow cytometry. 
ix. RNA isolation and quantitative real-time PCR        
      Total RNA was extracted using TRI Reagent (Molecular Research Center, Inc., Cincinnati, 
OH). Residual DNA was removed using DNA-free DNase (Ambion, Austin, TX). First-strand 
cDNA was synthesized using M-MLV reverse transcriptase (Invitrogen). Quantitative RT-PCR 
(qRT-PCR) was performed on an ABI 7500 system (Applied Biosystems, Foster City, CA) using 
SYBR Green I detection and gene-specific primers. Each sample was run in triplicate. The 
fluorescent signal was only detected in the amplification step for each cycle. A melt curve was 
generated to check the specificity of the amplification at the dissociation stage. 18S rRNA was 
used as an internal control. The relative amount of each gene of interest was normalized against 
18S rRNA from the same cDNA sample and calculated with the equation 2
-∆Ct
 and fold change of 
gene transcript levels between different samples was calculated with the equation 2
-∆∆Ct
, where 
∆Ct =Ct18s-Ctgene and ∆∆Ct=∆CtsampleA-∆CtsampleB. Primers are listed in Table 2. 
        For quantification of miRNAs, 5 μg of total RNA was poly A-tailed using A-Plus™ Poly A 
Polymerase tailing kit (Epicentre Biotechnologies, Madison, WI). 1.5 μg of poly A-tailed RNAs 
were reversed-transcribed into cDNA using oligo dT primers and M-MLV reverse transcriptase. 
qRT-PCR was performed using the target mature miRNA sequence as the forward PCR primer 
and a universal primer (5’- GCGAGCACAGAATTAATACGACTCAC-3’) as the reverse primer. 
U6 snRNA was used as an internal control. The relative amount of each miRNA to U6 snRNA 
was calculated by the comparative Ct method using the equation 2- (CtmiRNA –CtU6). Primers are 





Table 2 qRT-PCR Primers for mRNA 
 
Table 3 qRT-PCR Primers for miRNA 
 
x. MicroRNA microarray printing, hybridization and data analysis         
         The microRNA microarray was in-house printed using miRCURY LNA™ ready-to-spot 
probe set 11.0 (Exiqon). Four hundred ng of total RNA from mouse iPSCs or ACE II were 
labeled with Hy3 or Hy5 using miRCURY LNA™ microRNA power labeling kit (Exiqon). 
Mouse iPSC RNAs labeled with Hy3 were paired and mixed with AEC II RNAs labeled with 
Hy5. To eliminate dye bias, dye swap was performed. Slides were hybridized with the mixed 
Hy3/Hy5 or Hy5/Hy3 labeled RNAs for 16 to 18 h at 56°C. After hybridization, the slides were 
stringently washed and dried. The hybridized slides were scanned with ScanArray Express 
(PerkinElmer Life and Analytical Sciences, Boston, MA). The images were imported into 
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GenePix 5.0 pro (Axon Instruments, Inc. Union City, CA) for data extraction. The image and 
exported raw data were imported into Realspot software developed by our laboratory for quality 
test and Lowess normalization (90). The miRNAs with an average quality of less than 1 were 
filtered. To identify differentially expressed miRNAs, a two-tailed Student’s t-test assuming 
unequal variance was performed between iPSCs and ACE II groups. P < 0.05 was considered to 
be significant. 
xi. Target genes and pathway analysis of miR-29a 
        The pathways and targets of miR-29a were predicted by the web-based software programs 
Pictar (http://pictar.mdc-berlin.de/) and TargetScan (URL: ttp://www.targetscan.org/mmu_50/).  
xii. Vector construction 
      To construct microRNA expression vectors, pri-miRNA was amplified by PCR using specific 
primers and human genomic DNA. The fragments were inserted into a lentiviral vector 
(Clontech, San Jose, CA) at the XhoI and EcoR I sites (91). A similar size non-relevant genomic 
DNAsequence was used to construct a control vector (miR-con). The lentiviruses were generated 
in HEK 293T cells using Lenti-X HTX Packaging Mix (Clontech, Mountain View, CA), then 
titered and stored at -80°C until use. 
xiii. Construction of 3’-UTR luciferase reporter vectors  
       We cloned the binding sites of target genes by PCR-amplification from mouse genomic DNA 
into the pmirGLO vector (Promega, Madison, WI) downstream of a firefly luciferase reporter 
gene using the Nhel I and Sal I restriction sites. We used over-lapping PCR to construct luciferase 
reporters with mutations in the 3’-UTR of genes with miR-29a binding sites. We first amplified 
the binding site of the target gene as two fragments with overlapping mutation sites using two 
primer sets.  The annealing two fragments were then used as a template to amplify the mutant 




Table 4 Primers for vector construction 
 
xiv. Dual luciferase reporter assay         
       For the 3’-UTR reporter assay, HEK 293T cells were seeded in a 96-well plate (2 x 10
4
 cells/ 
well). After being in culture for 24 h, the cells were co-transfected with 5 ng of wild-type or 
mutant 3’-UTR luciferase reporter construct and 100 ng of miR-29a or let-7b expression plasmid 
using lipofectamine 2000 (Invitrogen). The empty pmirGLO vector was used as a negative 
control. Cells were harvested 24 h after transfection and dual luciferase activities were measured. 
Firefly luciferase activity was normalized against Renilla luciferase activity.  
       For studies of pathway activity in iPSCs, iPSCs were cultured in differentiation medium with 
Activin A (20 ng/mL) for 6 days and with FGF-2 (50 ng/mL) for 5 days. The cells were then 
seeded in a 96-well plate at a density of 2 x10
4
 cells/well. After being in culture for 24 h, the cells 
were transfected with 50 ng of miR-29a, miR-22 or let-7b expression vector and 100 ng of ERK, 
JNK or Wnt/β-catenin pathway luciferase reporter construct (SABiosciences, Frederick, MD). 
miR-con was used as a vector control. 24 h after transfection, epidermal growth factor (EGF) (10 
ng/well), phorbol 12-myristate 13-acetate (PMA) (1 ng/well) or Wnt3a conditioned medium (50% 
v/v) were added. After 18 h stimulation, the cells were harvested. ERK, JNK and Wnt/β-catenin 
transcriptional activities were measured using the Dual Luciferase Reporter Assay System. Data 
were expressed as a ratio of firefly luciferase activity to Renilla luciferase activity.  
      For studies of pathway activity in MSC, HEK293T cells were seeded in a 96-well plate at a 
density of 2 x10
4
 cells /well. After being in culture for 24 h, the cells were transfected with 50 ng 
of miR-29a expression vector and 100 ng of ERK-MAPK or JNK-MAPK pathway-luciferase-
reporter construct (SABiosciences, Frederick, MD). miR-con was used as a vector control. 24 h 
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after transfection, epidermal growth factor (EGF) (10 ng/well) or phorbol 12-myristate 13-acetate 
(PMA) (1 ng/well) were added. After 18 h stimulation, the cells were harvested. ERK-MAPK or 
JNK-MAPK transcriptional activities were measured using the Dual Luciferase Reporter Assay 
System. Data were expressed as a ratio of firefly luciferase activity to Renilla luciferase activity. 
xv. Western blot 
        For studies of iPSCs, iPSCs were infected with miR-29a lentivirus at a multiplicity of 
infection (MOI) of 50. The lentivirus containing miR-con was used as a virus control (VC). After 
48h, the cells were lysed in lysis buffer (Thermo Scientific, Rockford, IL). DC protein assay kit 
(Bio-Rad, Hercules,CA) was used to determine protein concentrations. Twenty µg of protein 
extracts were separated by 10% SDS-PAGE and then transferred onto nitrocellulose membranes. 
Proper transfer was ensured by staining the membrane with Ponceau S. Membranes were blocked 
overnight with 5% dried skimmed milk powder in 100 mM Tris-buffered saline plus 0.1% Tween 
20 (TBST). Then, the membranes were incubated at 4°C overnight with primary antibodies: 
rabbit polyclonal anti-DUSP2 (1:500, Abcam, Cambridge, MA), rabbit polyclonal anti-DUSP9 
(1:500, Abcam) or rabbit monoclonal anti-GAPDH (1:1000, Cell Signaling Technology, Beverly, 
MA). After being washed with TBST three times, the membranes were incubated with secondary 
antibodies (goat anti-rabbit antibody conjugated to horseradish peroxidase (HRP) (Bio-Rad, 
Hercules, CA) for 1 h. Blots were washed again and target proteins were visualized using the 
enhanced chemiluminescence detection system.  
          For studies of MSCs, MSCs were infected with miR-29a lentivirus at a multiplicity of 
infection (MOI) of 50. The lentivirus containing miR-con was used as a virus control (VC). After 
48h, the cells were lysed in lysis buffer (Thermo Scientific, Rockford, IL). DC protein assay kit 
(Bio-Rad, Hercules, CA) was used to determine the protein concentration. Twenty µg of protein 
extracts were separated by 10% SDS-PAGE and then transferred onto nitrocellulose membranes. 
Proper transfer was ensured by staining the membrane with Ponceau S. Membranes were blocked 
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overnight with 5% dried skimmed milk powder in 100 mM Tris-buffered saline plus 0.1% Tween 
20 (TBST). Then, the membranes were incubated at 4°C overnight with primary antibody: rabbit 
polyclonal to DUSP2 (1:500, Abcam, Cambridge, MA). After being washed with TBST three 
times, the membranes were incubated with horseradish-peroxidase-conjugated anti-(Rabbit-IgG) 
(1:2000) (Bio-Rad, Hercules, CA) for 1 h. Blots were washed again and the target protein was 
visualized using the enhanced chemiluminescence detection system.  β-actin (Sigma) was used as 
a loading control.  
xvi. Proliferation assay 
         The 5-bromo-2- deoxyuridine (BrdU) assay of iPSC-derived AEC II or MSC- derived AEC 
II was carried out to assess cell proliferation using a cell proliferation assay kit (Millipore, 
Temecula, CA) according to the manufacturer’s instructions Absorbance, which reflects the 
incorporation of BrdU into the cell DNA and thus transition through the cell cycle, was read at 
450 nm. Freshly isolated primary AEC II were used as a positive control. 
xvii. Surfactant lipid secretion assay 
 
           Freshly isolated primary AEC II from wild-type C57BL/6 mice and cells derived from 
iPSCs or MSCs of the 11th day with miR-29a in the presence or absence of DCI were cultured in 
96-well plates overnight.  Cells were then washed twice by PBS and DMEM containing 10% FBS 
was added. The cells were incubated at 37°C for 30 min. Culture medium was removed as a zero 
time control (0 h) for one set of wells. Cells were stimulated with lung surfactant secretagogues 
(100 µM ATP, 0.1 µM PMA and 10 µM terbutaline; ATP+PMA+Terb) for 2 h at 37°C. 
Unstimulated cells in parallel cultures were used as controls. At the end of incubation, 
phosphatidylcholine in both medium and cell lysate was measured using a phosphatidylcholine 
assay kit (Abcam, Cambridge, MA) following the manufacturer's instructions. Surfactant 
secretion was expressed as a percentage [(nmol in medium/nmol in medium and cell lysate) x 
100]. All of the secretion data were corrected by subtracting the value of 0 h.  
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xviii. ELISA for SP-C 
         ELISA was performed on cell culture medium collected before and after stimulation of 
iPSC-AEC II, MSC-AEC II or freshly isolated primary AEC II to quantify secreted SP-C using a 
SP-C ELISA kit (MyBiosource, San Diego, CA) according to the manufacturer’s instructions. 
The stimulation method is as the same as that used in the surfactant lipid secretion assay. SP-C 
values were normalized to the total number of cells. 
xix. Transmission electron microscopy 
                    Differentiated cells were fixed in 4% paraformaldehyde for 1 hour. Cells were washed 3 
times in 0.1M phosphate-buffered saline (PBS) pH 7.4 for 15 minutes each wash.  After then, 
cells were dehydrated through an ethanol series (50%, 70%, 90%, 95% & three times in 100% 
ethanol) for 15 minutes each and were washed three times for 15 minutes each in propylene 
oxide. The cell pellet was placed in 1:1 propylene oxide and Poly/Bed overnight.  The next day 
the vials were uncapped and left under the fume hood until most of the solvent had evaporated.  
100% Poly/Bed was gently added to the cell pellet and the samples were placed in an oven at 60 
C to polymerize for 48 hours. Embedded cells were sectioned and picked up on carbon film TEM 
grids.  Grids were stained with Reynold’s lead citrate stain followed by 2.5% uranyl acetate.  
Cells were imaged on a JEOL JEM-2100 transmission electron microscope. 
xx. Induction of pulmonary emphysema and treatment 
       Lung emphysema was induced in mice (C57BL/6, female, 8 weeks) by intratracheal 
instillation of elastase (Sigma, St. Louis, MO) at a dose of 0.25 U per mouse. Two weeks after 
elastase administration, mice were randomly divided into 3 groups (n>5 each group) which were 
intratracheally administered 50 ul PBS only, 50 ul AEC II differentiated from miR-29a-
engineered MSCs, or miR-con-engineered MSCs from male mice (500,000 cells per mouse). 
Mice were sacrificed after 1 week for analysis. Intratracheal instillation of PBS instead of elastase 
was used as blank control in a parallel group.  
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          To determine whether the intratracheally instilled male cells stayed in the female lungs, 
lung tissue from each mouse was harvested 1 week after intratracheal injection of cells and 
genomic DNA was prepared using the Genomic DNA Purification Kit (Promega, Madison, WI). 
DNA from each mouse was analyzed by qRT-PCR as previously described (92). Cytokine mRNA 
levels were also analyzed by qRT-PCR as described in “Quantitative real-time PCR”. 
xxi. Morphological assessment 
 
        The mean linear intercept (MLI) was used to assess the morphology of mouse lungs. MLI 
was performed as a measure of interalveolar wall distance and determined by light microscopy at 
a magnification of 20X. The MLI was obtained by dividing the total length of a line drawn across 
the lung section by the total number of intercepts encountered in 50 lines per each lung. 
xxii. Statistics 
          For comparisons across more than 2 groups, statistical analysis was performed using one-
way ANOVA followed by Tukey's post hoc test. For comparisons of 2 groups, statistical analysis 
was performed using two-tailed student t-test assuming unequal variance. Statistical difference 








III-1:  MicroRNA-26b modulates the NF-B pathway in bovine alveolar macrophages  
           by regulating PTEN 
 
i. Viability and purity of bovine macrophages 
 
The viability of the isolated bAMs were 72 ± 1.8 % and 92 ± 0.5% (mean ± SE, n=9) before 
and after attachment as revealed by trypan blue staining, respectively (Fig. 1A). The purity of the 
attached bAMs was determined by Wright’s Giemsa staining and immunostaining for the surface 
antigen CD68, which is a cell surface marker for macrophages. The immunostaining showed that 
96.1 ± 0.5% (means ± SE, n=9) cells were positive for CD68 (Fig. 1B). Only cell preparations 
containing bAMs with > 95% purity were used for our studies. 
ii. LPS induces time-dependent cytokine mRNA expression and nitric oxide                    
    production in bAMs  
LPS induces rapid production and release of inflammatory cytokines and chemokines 
known to be involved in lung inflammation and acute lung injury (93). To evaluate the role of 
LPS of E.coli (O55:B5) in pathogenesis of BRD, we investigated its in vitro effects on cultured 
bAMs. We incubated bAM monolayers with LPS for various time periods and assessed the 
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activation of bAMs by measuring cytokine mRNA expression. TNF-α and IL-6 mRNA 
expression peaked at 1 h after LPS stimulation of bAMs (Fig. 2A, B) while IL-1β and IL-10 
mRNA expression peaked at 6 and 36 h post-LPS exposure, respectively, as compared to 
untreated bAMs (Fig. 2C, D).   
It is well known that nitric oxide generated from LPS-stimulated bAMs causes cytotoxic 
injury to pulmonary cells (94). NO also plays an important role in numerous pathophysiological 
conditions including inflammation, and is induced in a nuclear factor (NF)-κB-dependent manner 
(95-97). To investigate the time course of LPS on NO production, bAMs were treated with LPS 
for 0, 1, 6 and 36 h. LPS markedly enhanced NO production as detected in the culture 
supernatant, reaching a maximum at 6 h post-LPS stimulation (Fig. 2E).  Here, we demonstrated 
that E. coli LPS increased cytokine mRNA expression and nitric oxide production in bAMs. 





Fig. 1: Identification of bAMs by Wright’s Giemsa and immunostaining. (A) Wright’s 
Giemsa staining. bAMs were identified by their large, nonlobulated, and dark nuclei and large 
amounts of cytoplasm. (B) Immunostaining using antibodies against the cell surface antigen 
CD68 for macrophages. Upper panels, CD68 antibody; Lower panels: negative control without 
the primary antibody. Scale bar is 50 m.  
 
 
Fig. 2: LPS induces mRNA expression of cytokines and NO production from bAMs. bAMs 
were stimulated with LPS (1 μg/ml) for 0-48 h. Controls were bAMs without LPS stimulation. 
The mRNA expression of TNF-α (A), IL-6 (B), IL-1β (C), and IL-10 (D) was measured by real-
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time PCR using 18S rRNA as an endogenous control. (E) NO production in the medium was 
determined using the Griess reagent in triplicate. Data were expressed as a fold change relative to 
0 h control. Results are shown as means ± SE. *P<0.05 vs. 0 h (n=3 cell preparations). 
 
iii. miR-26b is dynamically changed in bAMs after LPS stimulation 
Based on our preliminary microRNA microarray studies, we found that miR-26b was a 
LPS-responsive miRNA in bAMs and confirmed the microarray data by qRT-PCR (Fig. 3). miR-
26b expression in bAMs was increased in the early phase, but decreased in the later stages after 
LPS stimulation.  
 
Fig. 3: miR-26b expression in LPS-stimulated bAMs. bAMs were treated with LPS (1 µg/ ml) 
for 0, 1, 6 and 36 h. miRNA expression level was determined by miRNA microarray and real-
time PCR. Each expression ratio (LPS to common reference control) was log2 transformed. The 
miRNA signals obtained from the miRNA microarray from control and LPS treated samples were 
compared using a two-tailed Student’s t-test. Results are expressed as means ± SE.  * P< 0.05 vs 




iv. miR-26b enhances LPS-induced mRNA and protein expression of TNF-α, IL-8, IL-1β 
and IL-10 but represses that of IL-6 
We further explored whether miR-26b regulates inflammatory cytokine mRNA levels in 
LPS-stimulated bAMs.  We first determined the miR-26b expression level after infecting bAMs 
with different MOIs of miR-26 lentivirus or control lentivirus (VC).  Maximal expression of miR-
26b was achieved at a MOI of 50 (Fig. 4 A). We then infected bAMs with miR-26b lentivirus or 
VC at a MOI of 50 and challenged with LPS for 0, 1, 6 and 36 h. The blank control group (BC) 
was bAMs without virus infection. As seen in Fig. 4 B-F, the combination of miR-26b and LPS 
greatly augmented TNF-α, IL-8, IL-1β and IL-10 mRNA expression. However, miR-26b 
markedly reduced the level of IL-6 mRNA, consistent with the report that IL-6 is a direct target of 
miR-26b (98).  
Cytokine protein production in culture supernatant of bAMs was quantified by ELISA. In 
cells doubly challenged with LPS and miR-26b, we detected a significant increase in TNF-α, IL-
8, IL-1β and IL-10 and a decrease in IL-6 in the bAM supernatant at 6 h, as compared with the 
levels of these cytokines in VC treated with LPS (Fig. 4G-K). The trend is consistent with the 
change in mRNA levels.  
v. miR-26b promotes LPS-induced NO production 
Since NO is up-regulated by LPS and proinflammatory cytokines, we next examined NO 
production in miR-26b-challenged bAMs. NO production was increased after 6 h of LPS 
stimulation in lentiviral miR-26b-infected bAMs compared to VC-infected bAMs but this effect 
did not reach the significant level (Fig. 4L).  These results suggest that miR-26b and LPS 
synergistically enhance TNF-α, IL-8, IL-1β and IL-10 but repress IL-6 expression at the mRNA 
level, resulting in enhanced TNF-α, IL-8, IL-1β andIL-10 but decreased IL-6 protein levels in the 











































Fig. 4: miR-26b enhances LPS-induced TNF-α, IL-8, IL-1β and IL-10 mRNA and protein 
expression and NO production, but represses IL-6 mRNA and protein expression. bAMs 
were infected with various multiplicity of infection (MOI) of miR-26b lentivirus. (A) miR-26b 
expression level was determined by real-time PCR. Data was expressed as a fold change to 0 h 
VC. Results are expressed as means ± SE (n=3 cell preparations). bAMs were infected with 
lentiviruses expressing miR-26b or the lentiviral control vector (VC) at a MOI of 50. bAMs that 
were not infected with lentiviruses served as the blank control (BC). Then, bAMs were incubated 
with or without LPS (1 µg/ml) for 1, 6 and 36 h. The mRNA expression of TNF-α (B), IL-8 (C), 
IL-1β (D), IL-10 (E) and IL-6 (F) at indicated time points was analyzed by real-time PCR. The 
expression of each gene was normalized to the average of BC control samples at 0 h.  TNF-α (G), 
IL-8 (H), IL-1β (I), IL-10 (J), IL-6 (K) and NO (L) in the culture supernatant were assayed with a 
specific ELISA kit or Griess reagent (for NO). Results are expressed as mean ± SE. *P<0.05 vs. 






vi. PTEN is suppressed by miR-26b 
To decipher how miR-26b regulates LPS-induced cytokine expression, we used the 
bioinformatics tool, Targetscan, to predict target genes of miR-26b. Among these potential 
targets, there are 3 binding sites in the 3’-UTR of PTEN, which is highly conserved in mammals 
including cows, humans, mice and rats. Furthermore, PTEN inhibition activates Akt, which 
consequently activates IB kinase (IKK), leading to degradation of IB and nuclear translocation 
of the transcription factor NF-κB (99).  Therefore, we chose PTEN for further analysis.  
To verify whether PTEN is a potential target of miR-26b, Raw 247 cells were co-
transfected with the PTEN 3’-UTR firefly luciferase reporter vector and miR-26b or the control 
vector, miR-Con. Due to the length of the PTEN 3’-UTR, we cloned binding sites 1 and 2 into 
one luciferase reporter vector (PTEN1-WT), and cloned binding site 3 into a second reporter 
vector (PTEN2-WT) (Fig. 5A). We found that miR-26b suppressed activities of both PTEN1 and 
PTEN2 (Fig. 5B). When we mutated the binding site 1 or 2 in PTEN1 (PTEN1-M1 or PTEN1-
M2), the inhibition of the reporter activities by miR-26b was reduced compared to PTEN1-WT. 
Furthermore, the mutation of both binding sites PTEN1-M1+M2) completely abolished the miR-
26b inhibition. Similarly, the mutation of the binding site 3 in PTEN2 (PTEN2-M3) also resulted 
in no inhibition of the reporter activity by miR-26b. These results suggest that the three binding 
sites in 3’-UTR of PTEN are all involved in the binding of miR-26b. 
To further confirm the results, western blotting and qRT-PCR were used to determine the 
endogenous protein and mRNA expression levels of PTEN at different time points paralleled by 
the same time points of the miR-26b response to LPS. The results showed that PTEN protein and 
mRNA levels was reduced at 1 h after LPS stimulation and increased at 6 h and 36 h after LPS 
stimulation (Fig. 5C, D). However, PTEN protein and mRNA levels have no change in the 
control condition (Fig. 5C, D). The results support the functional correlation of miR-26b and 
PTEN. Additionally, western blotting was used to determine the endogenous PTEN protein 
38 
 
expression in miR-26b-overexpressing bAMs as well. The result showed that the PTEN protein 
level was reduced by miR-26b overexpression (Fig. 5E, F). We thus concluded that PTEN is a 
target of miR-26b in bAMs.  
vii. miR-26b enhances LPS-induced NF-B signaling pathway activity 
PTEN is known to inhibit Akt phosphorylation and thus the NF-B pathway (100, 101). 
Therefore, we next investigated whether miR-26b can activate NF-B signaling. We first used a 
dual luciferase-reporter assay to assess the effect of miR-26b on the NF-B pathway. We found 
that miR-26b up-regulated the activity of the NF-B-luciferase reporter construct after LPS 
stimulation compared with the control vector, miR-Con (Fig. 6A). Then, we determined the effect 
of miR-26b on LPS-induced phosphorylation of Akt, IKK, IBα and P65. miR-26b greatly 
enhanced the phosphorylation of Akt, IKK, IBα and P65 after a 15-min LPS stimulation (Fig. 
6B). Thus, these results show that miR-26b and LPS cooperatively up-regulate the NF-B 




Fig. 5: PTEN is a target of miR-26b. (A) The potential interaction between miR-26b and the 
putative binding sites in the 3’-UTR of the bovine PTEN gene. Mutations of bta-miR-26b binding 
sites in the 3’-UTR of bovine PTEN are indicated. (B) 3’-UTR luciferase reporter assays. 
HEK293T cells were co-transfected with wild-type (WT) PTEN1, PTEN2 or their mutants (M1, 
M2, M1+M2 or M3) and miR-26b or miR-con for 24 h. Firefly luciferase activity was normalized 
to Renilla luciferase activity. The results were expressed a ratio of empty pmirGLO vector + 
miR-con (mean ± SE). *P<0.05 vs. miR-con (n=3 cell preparations). (C) bAMs were stimulated 
with LPS (1 μg/ml) for 0-36 h. Controls were bAMs without LPS stimulation. The protein 
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expression level of PTEN was measured by western blotting. (D) the mRNA levels of PTEN at 
the same time points of LPS stimulation were measured by real-time PCR using 18S rRNA as an 
endogenous control. *p<0.05 vs. miR-con at the same time point; **P<0.05 vs. miR-26b at 0 h 
stimulation (n=3 cell preparation). (E) Western blotting for PTEN in the infected bAMs without 
lentivirus (BC) or with lentivirus expressing miR-26b or the lentiviral control vector (VC). (F) 
The bands were quantified by ImageJ. The relative PTEN expression levels were normalized to β-
actin. Results are expressed as mean ± SE. *P<0.05 vs. BC (n=3 cell preparations). 
 
 
Fig. 6: miR-26b activates NF-κB signaling. (A) Raw 246.7 cells were co-transfected with a NF-
B luciferase-reporter construct and miR-26b or miR-Con. After 24 h culture, cells were 
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stimulated with or without LPS (CON).  Blank Control (BC): Raw 246.7 cells transfected with 
only NF-B luciferase-reporter construct. The firefly luciferase activity was normalized to 
Renilla luciferase activity. Results are expressed as fold change over blank control (BC). Results 
are expressed as mean ± SE. **P<0.05 vs. miR-Con with LPS, *P<0.05 vs. CON (n=3 cell 
preparations). (B) Western blot analysis of phosphorylated Akt, Ikk, IκBα and p65 in lysates from 
bAMs infected with miR-26b or control lentivirus (VC) at a MOI of 50 for 16 h, and then treated 
for 0 – 60 min (above lanes) with LPS. Blank control (BC): bAMs without virus infection. 
 
viii. PTEN silencing enhances LPS-induced cytokine expression and activates the    
       NF-B signaling pathway 
           In order to assess the role of PTEN in the LPS-induced NF-B signaling pathway and in 
inflammatory responses in bAMs, we silenced PTEN using a PTEN shRNA lentivirus to see 
whether the cytokine mRNA expression and NF-B signaling pathway were affected. PTEN 
shRNA significantly reduced the expression of PTEN protein in bAMs (Fig. 7A).  
          To determine whether silencing PTEN causes the same cytokine responses as miR-26b in 
LPS-induced bAMs, bAMs were infected with PTEN shRNA lentivirus or the control lentivirus 
(Con-shRNA) at a MOI of 50 and then treated with LPS for 0, 1, 6 and 36 h after infection. 
Similar to miR-26b, PTEN silencing markedly increased the mRNA expression of TNF-α and IL-
1β at 1 and 6 h, respectively (Fig. 7B, D). However, PTEN silencing enhanced IL-8 and IL-10 
mRNA expression at 36 h rather than at 1 or 6 h as for the case of miR-26b (Fig. 7C, E). In 
contrast to miR-26b, which decreased the mRNA expression of IL-6 (Fig. 4F), PTEN silencing 
increased IL-6 mRNA level (Fig. 7F). This is consistent with the observation that IL-6 is a direct 
target of miR-26b (98).  
          To investigate the molecular mechanism by which PTEN silencing influences the LPS-
induced NF-B pathway in bAMs, we determined the phosphorylation of the components 
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involved in the pathway by western blotting (Fig. 8). The phosphorylation of Akt, IKK, IBα, 
and p65 was enhanced by PTEN silencing after 15 min of LPS stimulation in bAMs, which is the 


























































Fig. 7: PTEN silencing promotes LPS-induced TNF-α, IL-8, IL-1β, IL-10 and IL-6 mRNA 
expression. bAMs were infected with PTEN silencing lentivirus (PTEN shRNA) or virus control 
(Con shRNA) and cultured for 24 h. Blank control (BC): bAMs without virus infection. (A) 
Western blot analysis was performed to determine PTEN expression. (B-F) infected or un-
infected bAMs were stimulated with or without LPS (1 µg/ml) for 1, 6 and 36 h. The mRNA 
expression of TNF-α (B), IL-1β (C), IL-8 (D), IL-10 (E) and IL-6 (F) at indicated time points was 
analyzed by real-time PCR. The expression of each gene was normalized to the average of BC 





















Fig. 8: PTEN silencing activates NF-B signaling in bAMs. Western blot analysis of 
phosphorylated Akt, Ikk, IκBα and p65 in lysates of bAMs infected with lentiviruses expressing 
PTEN shRNA or vector control (Con shRNA) at MOI=50 for 16 h, and then treated for 0 – 60 
min (above lanes) with LPS. Blank control (BC): bAMs without virus infection. 
 
III-2:    MicroRNA-29a Efficiently Promotes the Differentiation of Mouse Induced       
             Pluripotent Stem Cells and Mesenchymal Stem Cells into Alveolar Epithelial       





i. Characterization of iPSCs  
      We first characterized iPSCs using immunostaining and qRT- PCR. The iPSCs expressed the 
pluripotent markers, NANOG and SSEA-4 as revealed by immunostaining (Fig 9A). qRT-PCR 
analysis showed that iPSCs had a high level of mRNA expression of pluripotent markers,  Sox2, 
Oct4, Nanog, and Dnmt3b. These markers were absent in MEF feeder cells except Dnmt3b with a 
low expression (Fig 9B). NANOG-positive cells were 65 ± 0.67% and 95 ± 1.34% (mean ± SE, 
























Fig. 9: Identification of mouse iPSCs by immunostaining and qRT-PCR. (A) Representative 
images of immunostaining for pluripotent markers (Nanog and SSEA-1) in the iPSC colonies. 4, 
6-diamidino-2-phenylindole (DAPI) staining was used as a nuclear marker. Scale bar: 50 µm; (B) 
qRT-PCR analysis of mouse undifferentiated iPSCs compared with mouse MEF. Values for 
Nanog, Oct4, Dmnt3t, and Sox2 were normalized to 18S rRNA from the same cDNA sample. 
Results are shown as mean ± SE. *P<0.05 vs. MEF (n=3 cell preparations); (C) Purified and 
unpurified iPSCs were fixed and stained for Nanog. The nuclei were stained using DAPI. Scale 
bar: 100 µm; (D) Percentage of positive cells for Nanog. *P<0.05 vs. unpurified iPSCs (n=4). 
 
ii. Differentiation of iPSCs to AEC II 
        To optimize a proper culture condition to differentiate iPSCs into AEC II with high 




on collagen IV coated 6-well plates overnight and the medium was switched to the 
differentiation medium with or without Activin A for 6 days and with or without FGF-2 
for 5 days. We monitored mRNA expression of AEC II markers SP-C and SP-B during 
the differentiation process. Inclusion of activin A and FGF-2 significantly increased 
mRNA expression of SP-C and SP-B (Fig 10A) and decreased that of the iPSC marker, 
Nanog (Fig 10 B). Immunofluorescence analysis revealed that 29.19 ± 3.14% and 27.93 
± 5.86% (mean ± SE, n= 3 cell preparations) of the activin A and FGF-2-treated iPSCs 





























Fig. 10: Characterization of differentiated iPSCs. (A) mRNA levels of SP-B and SP-C in 
differentiated iPSCs as determined by real-time PCR. Control (black bar): iPSCs cultured in 
differentiation medium without Activin A and FGF-2 for 11 days; Activin (gray bar): iPSCs 
cultured in Activin A (20 ng/mL) for 6 days and cultured in differentiation medium without FGF-
2 for 5 days; Activin+FGF-2 (white bar): iPSCs cultured in Activin (20 ng/mL) for 6 days and 
cultured in FGF-2 (50 ng/mL) for 5 days. *P<0.05 vs. control (n=3 cell preparations); (B) mRNA 
level of the iPSC marker Nanog in differentiated cells as determined by qRT- PCR. iPSCs were 
cultured in normal medium or differentiation medium with Activin A (20 ng/mL) for 6 days and 
with FGF-2 (50 ng/mL) for 5 days. (C-E) Immunofluorescence analysis of the AEC II markers, 





nuclei were stained with DAPI. Scale bar: 50 µm. (E) Quantitation of SP-C and ABCA3-positive 
cells. *P<0.05 vs differentiated iPSCs (n=3) 
 
iii. Identification of miRNAs enriched in AEC II  
         Since miRNAs have been reported to induce the reprogramming of mouse and human 
somatic cells into iPSCs (15), we reasoned that certain miRNAs may be able to promote the 
differentiation of iPSCs into AEC II. To identify such miRNAs, we performed miRNA 
microarray analysis on iPSCs and AEC II to screen the miRNAs enriched in AEC II. For data 
analysis, the weak and bad spots were eliminated using RealSpot software according to the 
assigned QI. LOWESS normalization was performed for the remained spots. We found ten 
miRNAs (miR-19b, miR-30b, miR-451, miR-142-3p, miR-142-5p, miR-22, miR-23, miR-24, 
miR-29a and let-7b) are enriched in AEC II cells by by two-tailed Student’s t-test analysis 






Fig. 11: Verification of AEC II-enriched miRNAs. Total RNA was extracted from AEC II cells 
and iPSCs. miRNA levels were determined by microarray and qRT-PCR. Each value represents a 
normalized ratio to iPSCs. Results are mean ± SE, *P<0.05 vs iPSCs (n=3). 
 
iv. Effect of miRNAs on the differentiation of iPSCs to AEC II 
Among these 10 miRNAs enriched in AEC II, miR-22, miR-23, miR-29a and let-7b are 
highly expressed in adult lungs compared to fetal lung and miR-127, miR-19 and miR-210 at the 
late stage of fetal lungs were used as negative miRNA controls (91). Since the differentiation of 
AEC II occurs at the late stages of fetal lung development and continues until adulthood, 
overexpressing these miRNAs may induce the differentiation of iPSCs into AECs. iPSCs seeded 
on collagen IV-coated plates were infected with a lentiviral virus expressing a miRNA or control 
vector (VC) at a MOI of 50 for 24h. The cells were serum-starved overnight and then cultured 
under 3 conditions for 11 days: 1) differentiation medium containing no growth factor (control); 
2) differentiation medium with Activin A for the first 6 days (Activin); and 3) differentiation 
medium with Activin A for 6 days and then FGF-2 for 5 days (Activin + FGF-2). miR-22, miR-
29a, and let-7b markedly augmented the mRNA expression of AEC II markers SP-C, SP-B, and 
ABCA3 (Fig 12 A-C) in the complete differentiation medium (Activin + FGF-2). However, miR-
29a and let-7b reduced the mRNA levels of AEC I markers, T1α and aquaporin 5 (AQP5), while 
miR-22 only inhibited T1α mRNA expression (Fig 12D, E). To determine how many iPSCs were 
differentiated into AEC II, we immunostained the differentiated cells with antibodies for the AEC 
II marker, SP-C. The SP-C-positive cells were 50.55%, 51.33% and 61.06% of the total cells for 
miR-22, miR-29a and let-7b as compared to 29.46% in VC (Figure 12F). The trend is consistent 
with the changes in mRNA levels.  
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The mRNA expression of iPSC markers, cMyc, Klf, Nanog, and Sox was extremely low 
in the cells cultured in the complete differentiation media with or without miRNA overexpression 
compared to undifferentiated iPSCs (Figure 13).  
 Dexamethasone (10 nM), 8-bromoadenosine 3, 5- cyclic monophosphate (cAMP, 0.1 
mM), and isobutylmethylxanthine (IBMX, 0.1 mM) (DCI) can induce the maturation of human 
and mouse AEC II (102). We next examined the effect of DCI on miR-29a-induced 
differentiation of iPSCs into AEC II. Inclusion of DCI in the differentiation media markedly 
increased the mRNA expression of AEC II markers. The expression levels of SP-C, SP-B and 
ABCA3 in these cells were 76%, 78% and 57% of freshly isolated AEC II from mouse (Fig 14A). 
However, these cells expressed negligible amounts of the AEC I markers, T1-α and AQP5 in 
comparison with AEC I trans-differentiated from AEC II (Fig 14B). At the protein level, 88.01 ± 
1.7% cells are positive for SP-C in the presence of DCI compared to 51.33 ±9.4% in the absence 
of DCI (Fig 14C). These results indicate that DCI further enhances miR-29a-induced iPSC 

















































Fig. 12: AEC II and AEC I marker expression in miRNA-overexpressed differentiated 
iPSCs. iPSCs were infected with a lentivirus expressing a miRNA at a MOI of 50. Blank control 
(BC): iPSCs cultured in differentiation medium without miRNA infection. The cells were then 
cultured in differentiation medium with or without Activin A (20 ng/mL) for 6 days and with or 
without FGF-2 (50 ng/mL) for 5 days. mRNA expression levels of AEC II markers, SP-C, SP-B, 





and normalized to vector control (VC).  (F) SP-C-positive cells as determined by 


































Fig. 13:  mRNA expression levels of iPSC markers after differentiation. iPSCs were 
infected with a lentivirus expressing a miRNA at a MOI of 50. The cells were then 
cultured in differentiation medium with Activin A (20 ng/mL) for 6 days and with FGF-2 
(50 ng/mL) for 5 days. mRNA levels of Oct4 (A), Sox2 (B), cMyc (C) and Klf (D) in 
undifferentiated iPSCs and differentiated cells with miRNA overexpression were 
determined by qRT-PCR and normalized to iPSCs. BC: blank control; VC: vector 


































Fig.14:  Effect of DCI on iPSC differentiation. iPSCs were infected with a lentivirus expressing 
miR-29a at a MOI of 50. The cells were then cultured in differentiation medium with or without 
dexamethasone (10 nM), 8-bromoadenosine 3, 5- cyclic monophosphate (cAMP, 0.1 mM), and 
isobutylmethylxanthine (IBMX, 0.1 mM) (DCI) with Activin A (20 ng/mL) for 6 days and with 
FGF-2 (50 ng/mL) for 5 days. mRNA levels of AEC II markers, SP-C, SP-B and ABCA3 (A) and 
AEC I markers, T1α and AQP5 (B) were determined by qRT-PCR and normalized to 18S rRNA. 
SP-C-positive cells were determined by immunostaining (C). Freshly isolated AEC II from mice 
and AEC I trans-differentiated from mouse AEC II were used as positive controls. *P< 0.05 vs. 
miR-29a (n=3). 
 
v. ERK and JNK signaling pathways are up-regulated by miR-29a and let-7b  
      To decipher how miR-22, miR-29a and let-7b regulate the differentiation of iPSCs into AEC 
II, we used the web-based software PicTar to predict the pathways that miR-22, miR-29a and let-
7b regulate. ERK, JNK and Wnt/β-catenin are the predicted pathways for the action of miR-22, 
miR-29a and let-7b (Table 5). To experimentally verify the prediction, we utilized the pathway 




fused to the firefly luciferase reporter gene. We found that both miR-29a and let-7b up-regulated 
the ERK and JNK luciferase reporter activities, but had no effect on Wnt/β-catenin luciferase 
reporter activity (Fig 15). miR-22 also increased JNK reporter activity, but not those of ERK and 



































Fig. 15: miR-29a and let-7b up-regulate ERK and JNK signaling pathways but not the 
Wnt/β-catenin signaling pathway. iPSCs were cultured in differentiation medium with Activin 
A (20 ng/mL) for 6 days and with FGF-2 (50 ng/mL) for 5 days. The cells were then transfected 
with Wnt/β-catenin luciferase-reporter construct (A), JNK luciferase-reporter construct (B) or 
ERK luciferase-reporter construct (C) along with miR-22, miR-29a or let-7b for 24 h. After 18 h 
stimulation with Wnt 3a conditioned medium (50% v/v), PMA (1 ng/well) or EGF (10 ng/well), 
the dual luciferase activities were measured. Data was expressed as a ratio of firefly luciferase 
activity to Renilla luciferase activity. All experiments were carried out in triplicate. *P<0.05 vs 
non-stimulation. **P<0.05 vs miR-con with stimulation (n=3). 
 
 vi. DUSP2 is repressed by miR-29a   
The bioinformatics tool, Targetscan, predicts many target genes of miR-29a and let-7b 
involved in the ERK and JNK pathways (Table 5). Since they up-regulate ERK and JNK 
pathways, miR-29a and let-7b must target negative regulators of these pathways. Both Akt and 




and Akt2 and DUSP9 are the possible targets of miR-29a and let-7b for regulating MAPK 
pathways, respectively.  
To verify these predications, iPSC-derived AEC II were co-transfected with the 3’-UTR 
firefly luciferase reporter vector of DUSP2, Akt3, DUSP9 or Akt2 and miR-29a or let-7b or the 
control vector, miR-Con. We found that miR-29a and let-7b repressed the activities of DUSP2 
and DUSP9 3’-UTR reporters, respectively, but had no effects on those of Akt3 and Akt2 
(Fig16A, B). When we mutated the miRNA binding site in DUSP2 and DUSP9, miR-29a or let-
7b-mediated inhibition of the reporter activities were abolished.  
To further confirm the results, iPSC-derived AEC II were infected with a lentivirus 
expressing miR-29a or let-7b. miR-29a reduced the protein levels of DUSP2, but not DUSP9 (Fig 
16C). However, let-7b had no effects on DUSP2 and DUSP9 protein levels. We thus concluded 
that miR-29a activated ERK and JNK pathways through repressing DUSP2 (Fig 16D).  
 

























































Fig. 16: DUSP2 is a target of miR-29a. HEK 293T cells were transfected with 3’-UTR 





reporter or its mutant for DUSP9 or Akt2 with let-7b (B) for 24 h. Dual luciferase activities were 
measured. Firefly luciferase activity was normalized to Renilla luciferase activity. Data were 
expressed as mean ± SE. *P<0.05 vs. miR-Con (n=3). (C) Western blot analysis for DUSP2 and 
DUSP9. iPSCs were infected without lentivirus (BC) or with a lentivirus expressing miR-29a, let-
7b or miR-con (VC) for 48 h and DUSP2 and DUSP9 protein levels were determined by Western 
blot. (D) A proposed mechanism of miR-29a-mediated activation of ERK and JNK pathways in 
iPSCs through repression of DUSP2. 
 
vii. iPSC – derived AEC II cells are functional         
       AEC II proliferate and differentiate into AEC I when AEC I are damaged (102). We 
investigated whether the iPSC derived ACE II (iPSC-AEC II) were able to proliferate in vitro by 
BrdU assay. iPSC-AEC II did proliferate although less compared to mouse primary AEC II 
(Figure 17A).  
       When they were cultured on plastic dishes for 5-7 days, AEC II trans-differentiate into AEC I 
(102). To determine whether iPSC-AEC II can trans-differentiate into AEC I,  iPSC-AEC II or 
AEC II isolated from mice were cultured in DMEM with 10% FBS on plastic dishes for 7 days 
and AEC I and AEC II markers were determined by qRT-PCR. The trans-differentiated AEC I 
from iPSC-AEC II expressed a similar level of the AEC I markers, AQP5 and T1α as the trans-
differentiated AEC I from primary AEC II and expressed little of the AEC II markers, ABCA3, 
SP-B and SP-C (Figure 17B). While 78% of iPSC-AEC II expressed SP-C, 75% of the trans-
differentiated AEC I from iPSC-AEC II expressed T1α (Figure 17C-F).   
        One of the major functions of AEC II is to secrete lung surfactant (105). Lung surfactant 
secretagogues (ATP, PMA and terbutaline) stimulated the secretion of surfactant lipids by 3.9-
fold from iPSC-AEC II in comparsion with 5.5-fold from primary AEC II (Figure 18A). These 
lung surfactant secretagogues also increased secretion of the surfactant protein SP-C in both 
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iPSC-AEC II and primary AEC II (Fig 18B). These results suggest that iPSC-AEC II behave 



















































Fig. 17: iPSC- AEC II can proliferate and transdifferentiate into AEC I. iPSCs were infected 
with a lentivirus expressing miR-29a at a MOI of 50. The cells were then cultured in 
differentiation medium in the presence of DCI with Activin A (20 ng/mL) for 6 days and with 
FGF-2 (50 ng/mL) for 5 days and designated as iPSC-AEC II. (A) Cell proliferation as 
determined by BrdU labeling in freshly isolated AEC II and iPSC-AEC II. (B-F) Freshly isolated 
AEC II and iPSC-AEC II were cultured on plastic plates in DMEM for 7 days. mRNA levels of 
AEC I and AEC II cell markers were determined by qRT-PCR and normalized to 18S rRNA (B). 
SP-C and T1α-positive cells were determined by immunostaining before (C, D) or after 7-day 





Fig. 18: iPSC-AEC II can secrete lung surfactant lipid and protein. iPSCs were infected with 
a lentivirus expressing miR-29a at a MOI of 50. The cells were then cultured in differentiation 
medium in the presence of DCI with Activin A (20 ng/mL) for 6 days and with FGF-2 (50 
ng/mL) for 5 days and designated as iPSC-AEC II. Freshly isolated AEC II and iPSC- AEC II 
were cultured overnight and stimulated for 2 hours with lung surfactant secretagogues (100 µM 
ATP, 0.1 µM PMA and 10 µM terbutaline, ATP+PMA+Terb). Phosphatidylcholine (A) and SP-C 
(B) secretion were measured. Results are shown as mean ± SE. *P<0.05 vs. control (n=3). 
 
IV-2-2: MSCs 
i. Characterization of mouse bone marrow (BM)-MSCs 
 
        The cell surface markers of P2 BM-MSCs were determined by FACS. More than 95% of the 
MSC population expressed the stem-cell antigen 1 (Sca-1), tetraspanin proteins (CD9 and CD81) 
and β1-integrin (CD29) (Fig. 19). And, 62% of the MSC population expressed endoglin receptor 
(CD44) (Fig. 19). Additionally, these cells lacked expression (<1% positive) of the leukocyte 








Fig. 19: Flow cytometry analysis of cell surface markers of mouse MSCs. MSCs were isolated 
from bone marrow of C57BL/6 mice. P2 MSCs were stained with monoclonal antibodies 
conjugated to FITC, PE, or PE-Cy5 against Sca-1, CD9, CD29, CD44, CD81, CD11b, or CD45. 
Results are shown as mean ± SE, n=3. 
 
ii. Differentiation of MSCs to AEC II 
            To find the proper conditions to differentiate MSCs into AEC II, we used different 
matrices to drive the differentiation, including gelatin and collagen IV. We found that collagen IV 
but not gelatin can drive MSC differentiation into AEC II (data not shown).   
P2 MSCs were seeded on mouse collagen IV-coated 6-well plates overnight. On the 
second day, the medium was switched to the differentiation medium, small airway growth 
medium (SAGM). The cells were cultured for 11 days. In the parallel group, MSCs were cultured 
in MSC culture medium (Control) for 11 days. We observed that approximately 25% of MSCs 
differentiated into AEC II based on immunostaining for the AEC II marker SP-C (Fig. 20). The 
result indicated that SAGM medium could drive MSCs to differentiate into AEC II, but the 





Fig. 20: SP-C protein expression in differentiated MSCs. P2 MSCs were cultured in MSC 
medium or SAGM for 11 days. Cells were fixed and stained for SP-C (red). DAPI staining was 
performed for counting cells. (A) Fluorescent images. magnification: 20X. (B) Quantitation of 
SP-C-positive cells. Results are shown as means ± SE. *P< 0.05 vs. MSC medium (n=3). Scale 
bar: 50µm 
iii. miR-29a enhances differentiation of MSCs into AEC II 
We have previously identified several miRNAs that are enriched in AEC II and highly 
expressed in adult lungs, and have shown that some of those miRNAs can promote the 
differentiation of iPSCs into AEC II. We next asked whether those miRNAs could enhance the 
differentiation of MSCs into AEC II. To test the possibility, we infected MSCs with miR-22, 
miR-23, miR29a, and let-7b lentivirus or control virus (VC) at a MOI of 50 and cultured them on 
collagen IV-coated plates in the differentiation medium for 11 days. miR-210 was used as a 
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negative control. The parallel blank control group (BC) was MSCs without virus infection. miR-
29a markedly augmented mRNA expression of the AEC II markers, SP-C, SP-B, and ABCA3 
(Fig. 21A-C). Since AEC II can spontaneously differentiate into AEC I (106), we assessed the 
expression of AEC I markers T1α and aquaporin-5 (AQP5) by qRT–PCR in the differentiated 
cells. miR-29a significantly decreased the mRNA expression level of AEC I markers, T1α and 
AQP5 (Fig. 21D, E).  
In addition, we monitored the protein expression level of the AEC II marker, SP-C, by 
immunostaining in the differentiated cells. We found that approximately 55% of the miR-29a-
overexpressed MSCs were SP-C-positive compared to 25% of the VC-treated MSCs. (Fig. 22 A, 
B).  The typical characteristic organelle of AECII, lamellar bodies, were found in MSCs 
differentiated in the SAGM, and miR-29a increased the number of lamellar bodies (Fig. 22 C). 
Collectively, these results suggest that miR-29a can efficiently promotes the differentiation of 






















































Fig. 21: mRNA levels of AEC II and AEC I cell markers in differentiated MSCs with 
miRNA-overexpression. P2 MSCs were infected with a lentivirus expressing a miRNA or a 
virus control (VC) at a MOI of 50. The cells were then cultured in SAGM medium for 11 days. 
Blank control (BC) and virus control (VC) cells were also cultured in MSC complete culture 
media as a negative control (Ctl). mRNA levels of SP-C (A), SP-B (B), ABCA3 (C), T1α (D) and 
AQP5 (E) were determined by q-RT-PCR and normalized to 18S rRNA. Results are shown as 























































Fig. 22: SP-C protein expression and lamellar bodies in differentiated MSCs with miRNA-
overexpression. P2 MSCs were infected with a lentivirus expressing a miRNA or with a virus 
control (VC) at a MOI of 50. The cells were then cultured in SAGM medium for 11 days. Blank 
control (BC) and VC control cells were also cultured in MSC complete culture media as a 
negative control (Ctl). SP-C protein expression was determined by immunostaining. (A) 
Fluorescent images. Magnification: 20X. Scale bar: 50µm (B) Quantitation of SP-C-positive 
cells. Results are shown as means ± SE. *P<0.05 vs BC-SAGM. **P<0.05 vs VC-SAGM (n=3). 
(C) Electron microscopy images of lamellar bodies (LB) in the differentiated MSC overexpressed 





iv. DCI promotes miR-29a-mediated differentiation of MSCs into AEC II 
Since dexamethasone (10 nM), 8-bromoadenosine 3,5- cyclic monophosphate (cAMP, 
0.1 mM), and isobutylmethylxanthine (IBMX, 0.1 mM) (DCI) can induce the maturation of AEC 
II (102), we next examined the effect of DCI on miR-29a-mediated differentiation of MSCs into 
AEC II. The treatment of miR-29a and DCI strongly induced the mRNA expression levels of the 
AEC II cell markers (SP-C, SP-B and ABCA3) compared to miR-29a alone (Fig. 23A). The 
treatment with DCI appears to decrease the mRNA expression levels of AEC I markers, T1α and 
AQP5 although AEC I marker expression in these cells was negligable compared to AEC I (Fig. 
23B). 
Further characterization was done by immunostaining of SP-C and T1α. On day 11  of 
the differentiation, 90 ± 0.19% of the cells were positive for SP-C in the differentiated cells with 
miR-29a overexpression together with DCI compared to 54 ± 6.2 % in the absence of DCI Only 3 
± 0.3 % of the cells were positive for T1α (Fig. 23C, D). The differentiated cells mediated by 
miR-29a and DCI lost all the MSCs surface markers (2.4% Sca-1,2.1% CD9, 1.3% CD29, 1.5%, 
CD44, 1.4% CD81, 0.47% CD11b, 0.83% CD45). Taken together, these results suggest that DCI 








































Fig. 23: Effects of DCI on miR-29a-mediated differentiation of MSCs into AEC II. miR-29a 
overexpressed MSCs were cultured in SAGM with or without DCI for 11 days. The mRNA 
expression of SP-C, SP-B, and ABCA3 (A), T1α and AQP5 (B) was measured by qRT-PCR 
using 18S rRNA as an endogenous control.  Primary mouse AEC II was used as positive controls. 
(C) Immunostaining of the differentiated cells using anti-SP-C and anti-T1α antibodies. Scale bar: 
50µm (D) Quantitation of SP-C-positive cells. Results are shown as means ± SE. *P<0.05 vs 
miR-29a (n=3). 
 
v. DUSP2 is the target of miR-29a in MSCs 
DUSP2 has been reported to have an important role in differentiation. Recently, we have 
demonstrated that DUSP2 is the target of miR-29a in iPSCs. To examine whether DUSP2 is also 
target of miR-29a in MSCs, we infected MSCs with miR-29a lentivirus and performed Western 
blotting to determine the DUSP2 protein levels. A decreased protein level of DUSP2 was found 
in the MSCs infected with a miR-29a lentivirus compared to the cells infected with the control 
virus or blank control without virus infection. Let-7b had no effects on DUSP2 protein expression 
(Fig. 24).  
 
Fig. 24: miR-29a reduces DUSP2 level in MSCs. MSCs were infected with a lentivirus 
expressing miR-29a, let-7b or a virus control (VC). Blank control (BC) is the MSC without 




vi. miR-29a enhances MAPK signaling pathway  
DUSP2 is known to inhibit the MAPK signaling pathway by dephosphorylation of 
threonine and tyrosine residues on MAPKs (103). Therefore, we next investigated whether miR-
29a can activate the MAPK signaling pathway during differentiation as we found in the 
differentiation of iPSCs. 
We first used a dual luciferase reporter assay to assess the effect of miR-29a on the ERK 
or JNK pathway. miR-29a up-regulated the activity of both ERK and JNK luciferase reporters 
after stimulation compared to the control vector, miR-Con (Fig. 25A). Then, we determined the 
effects of the activators or inhibitors of ERK and JNK pathways on the MSC differentiation. As 
seen in Fig. 25B, the inclusion of ERK or JNK activator in the differentiation medium 
significantly increased the mRNA levels of SP-C. Additionally, the combination of ERK and 
JNK activators increased the SP-C mRNA level even more than any single activator (Fig. 25B). 
On the other hand, ERK and JNK inhibitors repressed the MSC differentiation mediated by miR-
29a (Fig. 25C). These results suggest that miR-29a promoted the differentiation of MSCs into 


























































Fig. 25: Role of ERK and JNK pathways in the differentiation of MSCs into AEC II. (A) 
HEK 293T cells were co-transfected with ERK or JNK luciferase-reporter construct and miR-29a 
or a vector control (miR-Con). The cells were stimulated with EGF or PMA. The firefly 
luciferase activity was normalized to Renilla luciferase activity. Results are expressed as fold 
change over control. *P<0.05. Error bars represent SE. (B) Effects of ERK and JNK activators on 
mRNA levels of SP-C.  MSCs were cultured in SAGM in the presence or absence of ERK 
activators (EGF) and JNK activator (Anisomycin and PMA) for 11 days and SP-C mRNA was 
determined by qRT-PCR. *P<0.05 vs. MSCs cultured without activators (n=3). Error bars 
represent SE. (C) Effect of ERK and JNK inhibitors on mRNA levels of SP-C. miR-29a-




(UO126) and JNK inhibitor (SP600125) for 11 days and SP-C mRNA was determined by qRT-
PCR. *P<0.05vs miR-29a+UO126, **P<0.05 vs miR-29a+SP600125 (n=3). Error bars represent 
SE. (D) Proposed mechanism of miR-29a-mediated activation of ERK and JNK pathways. 
 
 vii. MSC–derived AEC II are functional 
We first examined whether the miR-29a and DCI mediated MSC-differentiated AEC II 
(MSC-AEC II) were able to proliferate by BrdU assay. MSC-AEC II were able to proliferate 
although the proliferation rate was lower than that of the freshly isolated AEC II (Fig. 26A). 
AEC II trans-differentiate into AEC I when they are cultured on plastic dishes. We next 
determined whether MSC-AEC II could trans-differentiate into AEC I. MSC-AEC II were 
cultured in DMEM with 10% FBS for 7 days on plastic dishes and were then harvested for qRT–
PCR and immunostaining analyses. The mRNA expression of the AEC II markers, SP-C, SP-B 
and ABCA3, were significantly decreased, whereas the mRNA expression of the AEC I markers, 
T1α and AQP5 were significantly enhanced (Fig. 26B). Immunostaining demonstrated 86.01 % 
T1α positive cells and 3.8 % SP-C positive cells in the 7-day cultured MSC-AEC II (Fig. 26C, 
D). These results suggest that MSC-AEC II can proliferate and be trans-differentiated into  
AEC I. 
We next examined whether MSC-AEC II can secrete lung surfactant lipids and proteins. 
Phosphatidylcholine (PC) and SP-C were chosen as representatives of lung surfactant lipids and 
proteins. Lung surfactant secretagagues (ATP, PMA and terbutaline) stimulated PC secretion by 
4.6 folds in MSC-AEC II in comparsion with 5-fold from primary AEC II (Fig. 26E). ELISA 
measurements of SP-C protein in the cell culture supernatants indicated that lung surfactant 
secretagogues also increased SP-C secretion in freshly isolated AEC II and MSC-AEC II (Fig. 
26F). The data suggest that MSC-ACE II are able to secrete PC and SP-C. In conclusion, MSC-













































Fig. 26: Functional characterization of MSC-AEC II. MSC-AEC II were obtained by culturing 
miR-29a-overexpressed MSCs in SAGM in the presence of DCI for 11 days. Primary AEC II 






differentiation. MSC–AEC II or primary AEC II were cultured in DMEM for 7 days. mRNA (B) 
and protein (C) levels of AEC II and AEC I markers were determined by qRT-PCR and  
immunofluorescent staining. Scale bar: 50µm   Quantification of SP-C- or T1α-positive cells was 
presented in (D) *P<0.05 vs. MSC-AEC II Day 17; **P<0.05 vs MSC-AEC II (n=3). (E, F) Lung 
surfactant lipid and protein secretion. Primary AEC II and MSC-AEC II were stimulated for 2 
hours with lung surfactant secretagogues (100 µM ATP, 0.1 µM PMA and 10 µM terbutaline; 
ATP+PMA+Terb) Phosphatidylcholine secretion (E) and SP-C secretion (F) were measured. 
Results shown are mean ± SE. *P<0.05 vs. control (n=3 cell preparations). 
 
 viii. MSC-AEC II reduces elastase-induced airspace enlargement and lung inflammation, 
and limits elastase-induced weight loss in mice 
We next test whether MSC-AEC II function in vivo in the elastase-induced emphysema 
mouse model. Pulmonary emphysema is an important component of COPD which is 
characterized by reduced alveolar surface area and increased alveolar size (107). MSC-AEC II 
used for this study were the AEC II that were differentiated from MSCs mediated by miR-29a for 
11 days in SAGM in the absence of DCI (designated as miR-29a-MSC-AEC II). The vector 
control was AEC II that were differentiated from MSCs mediated by miR-con for 11 days in 
SAGM in the absence of DCI (designated as miR-Con-MSC-AEC II). Elastase was intratrachally 
administrated into the lungs of C57BL/6 mice. PBS was used as a control group. After two 
weeks, the mice with elastase injection were randomly assigned to receive intratracheal injections 
of miR-29a-MSC-AEC II, miR-Con-MSC-AEC II or PBS. The non-elastase control group was 
received PBS injection. The lungs were collected 1 week after the cell injection. 
To evaluate whether the injected male cells were retained in the female mouse lungs, we 
performed qRT-PCR to detect the presence of the Y chromosome. Low levels of Y-chromosome 
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DNA were detected in both miR-29a-MSC-AEC II and miR-Con-MSC-AEC II groups, but not in 
the non-elastase and elastase control groups (Fig. 27A).  
Histological analysis showed that elastase injection resulted in airway enlargement. This 
was reflected by a significant increase in the mean linear intercept (MLI) (Fig. 27 B-F). miR-
Con-MSC-AEC II reduced elastase-induced airway enlargement and miR-29a-MSC-AEC II 
decreased further compared to the elastase alone group.   
We also determined the levels of inflammatory cytokines in the lungs. The mRNA levels 
of TNF-α, IL-1β, IL-6, and MCP-1 were strongly increased by elastase compared to PBS (Fig. 27 
G-J). miR-29a-MSC-AEC II significantly decreased elastase-induced cytokine expression. 
However, miR-Con-MSC-AEC II had little effect.  
In addition to damaging pulmonary structures and inducing inflammation, elastase also 
induced significant total body weight loss compared to PBS control groups (Fig. 9K). miR-29a-
MSC-AEC II significantly limited the elastase-induced body weight loss (Fig. 9K). miR-con-
MSC-AEC II also limited the elastase-induced body weight loss, but this effect did not reach the 
significant level (Fig. 27K). 
These results support the conclusion that miR-29a-MSC-AEC II are able to ameliorate 





























































































Fig. 27:  Effect of MSC-AEC II treatment on elastase-induced airspace enlargement and 
lung inflammation. Female C57BL/6 mice were treated with elastase or PBS for 2 weeks, then 
intratracheally injected with PBS, miR-29a engineered male MSCs or miR-con engineered MSCs 
cultured in SAGM for 11 days. After 1 week treatment, the lungs were collected for analyses. (A) 
Percentage of male DNA within the lungs of female transplant mice after receiving an 
intratracheal injection of male miR-29a or miR-con MSC-AEC II. (B-E) Hematoxylin and eosin 
(H&E) of lung sections from mice treated by PBS (B), elastase (C), elastase plus miR-con-MSC-
AEC II (D), and elastase plus miR-29a-MSC-AEC II (E). (F) Mean linear intercepts (MLI). 
Results shown are mean ± SE. *P<0.05 vs. elastase group (n>5); **P<0.05 vs. miR-con-MSC-
AEC II group (n>5). (G-J) mRNA levels of TNF-α, IL-1β, IL-6 and MCP-1 in the lungs were 
determined by qRT-PCR. Results shown are means ± SE. *P<0.05 vs. elastase group (n>5); 
**P<0.05 vs. miR-con-MSC-AEC II group (n>5). (K) Body weight. Data was % of body weight 
at day 21 over that on day 0. *P<0.05 vs. elastase group (n>5); **P<0.05 vs. elastase-miR-con-









IV-1:  MicroRNA-26b modulates the NF-B pathway in bovine alveolar macrophages  
        by regulating PTEN 
       The expression and functions of miRNAs are cell- and tissue-specific. The role of miRNAs 
in the inflammatory response of bovine alveolar macrophages to LPS challenge has not been 
investigated in detail and certainly has not been explored in regards to BRD. In this study, LPS of 
E. coli was demonstrated to increase cytokine mRNA expression level and nitric oxide production 
by activating bAMs and miR-26b was found to be a LPS-responsive miRNA in bAMs that 
promoted bAM expression of inflammatory cytokines and nitric oxide production but not IL-6. 
miR-26b also enhanced NF-B pathway activity by targeting PTEN, therefore acting upstream of 
the NF-B pathway. Taken together, these data reveal that miR-26b promotes inflammatory 
responses in LPS-stimulated bAMs through the activation of the NF-B pathway by inhibiting 
PTEN (Fig. 28). Importantly, it raises the possibility for the development of novel therapeutic 
strategies for decreasing the morbidity associated with BRD by regulating miR-26b activity. 
        Previous evidence revealed that LPS from E. coli caused intensive enzymatic and oxidative 
response of bovine neutrophils in vitro and destructive neutrophil response was observed during 
the course of BRD (4). Therefore, in our studies we concentrated on the effect of LPS from E.coli 
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on bAMs as a responsible cause of lung injury. In this study, we demonstrated that E. coli LPS 
increased cytokine mRNA expression level and nitric oxide production by bAMs. 
 
 
Fig. 28: Proposed mechanism of miR-26b enhancement of LPS-stimulated NF-κB pathway 
through down-regulation of PTEN. 
 
 Alterations in gene expression including miRNA expression can regulate cellular 
responses to exogenous stimulation. LPS is one potential virulence factor and is known as an 
inducer of inflammation that plays a significant role in the lesion severity in lung tissue (26, 108). 
Since BRD is a multi-factorial complex phenotype, dissecting the molecular networks involved is 
essential for understanding the pathogenesis of BRD. Previous study has identified up-regulated 
and down-regulated miRNAs and associated signaling pathways in in bovine monocyte 
inflammatory response network during S. uberi infection (109). And, many LPS-responsive 
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miRNAs have been identified to have a role in cytokine secretion in other species (13, 110, 111).  
miR-223, for example, is down-regulated in RAW264.7 cells challenged with LPS, which leads 
to the up-regulation of signal transducer and activator of transcription 3 (STAT3) and promotes 
pro-inflammatory IL-6 and IL-1β transcription in mice (110). It is unknown if miR-223 has a 
similar role in alveolar macrophages. This is of interest since these cells play a critical role in the 
innate immunity against infections of BRD.  In our study, miR-26b was identified as an LPS 
responsive miRNA in bAMs. To our knowledge, this is the first report to study the function of 
LPS-responsive miRNAs in bovine alveolar macrophages and the first to report that miR-26b is 
an important regulator of the secretory activity of these cells.  
miR-26 is involved in many biological processes. It has been suggested that miR-26 may 
play a significant role in tumor formation, since miR-26 expression is reportedly decreased in 
various kinds of tumors as tumor-suppressor but increased in glioma (112). miR-26b was found 
to enhance human pituitary tumor cell behavior through the direct regulation of PTEN (113). It 
has been observed that estrogen-repressed miR-26a regulates numerous genes associated with cell 
growth and proliferation in breast tumors (114). Down-regulation of miR-26b was found in 
carcinoma-associated fibroblasts from estrogen receptor-positive breast cancers and enhanced cell 
migration and invasion (115). There have been studies regarding the function of miR-26b related 
to inflammatory responses that down-regulation of hsa-miR-26b expression may be involved in 
TNF-α, leptin and resistin-induced insulin resistance and inflammatory responses (116). In spite 
of all these studies, there are very few functional studies of miR-26b in bovine lungs associated 
with inflammation. We demonstrated that miR-26b promotes pulmonary inflammation by 
enhancing mRNA expression levels of TNF-α, IL-8, IL-1β and IL-10 but not IL-6, supporting 
previous findings that IL-6 is a direct target of miR-26b (98) and is conserved in bovine 
inflammatory cells. Furthermore, secreted cytokine protein levels mirrored those found in the 
mRNA, establishing that these changes are functionally significant. Interestingly, IL-8 mRNA 
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level enhanced by miR-26b is strongly higher than IL-8 protein level enhanced by miR-26b in 
LPS-activated bAMs. It indicates that the miR-26b mediated IL-8 protein secretion is less 
actively translated than the miR-26b mediated high level of IL-8 mRNA in LPS-activated bAMs. 
This leaves us an interesting direction to study in the future. In all, these findings add to the 
growing body of cell- and tissue-specific functions of miR-26b. 
NF-B is a transcription factor that controls a variety of important genes encoding 
transcriptional factors, adhesion molecules, cytokines and growth factors involved in 
inflammation and the immune response.  LPS is a potent activator of NF-B in alveolar 
macrophages (117). Because of its importance to many biological processes, NF-B activation 
and activity are tightly regulated by a battery of endogenous mechanisms. The excessive and 
prolonged production of pro-inflammatory mediators triggered by the NF-B pathway, such as 
TNF-α and IL-6, may result in tissue damage (118). Evidence is growing rapidly that establishes 
an important etiologic role of miRNAs in the initiation and progression of pathological 
inflammation and immune responses.  miRNA control of NF-B is emerging as a significant 
mechanism in disease and normal homeostasis (14).  
Studies have shown that the LPS-induced NF-B pathway is completed by LPS-induced 
up-regulation of let-7b and down-regulation of miR-125 through decreasing B-Ras2 expression 
which is an inhibitor of IKK leading to IB stabilization in primary human macrophages. (119). 
miR-155 affects the production of proinflammatory cytokines through the activation of NF-B by 
targeting IKKε in an epithelial cell line (120). Little is understood concerning the function of 
miR-26b in the regulation of NF-B signaling and to inflammation and immune responses in 
bAMs challenged with LPS. In this study, we proved that miR-26b up-regulates the LPS-
stimulated NF-B signaling pathway by suppressing PTEN in bAMs, providing new insight into 
the regulatory role that miR-26b plays in the NF-B pathway in alveolar macrophages. 
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PTEN is well known as a tumor suppressor gene and is frequently deleted or mutated in a 
wide variety of human cancers including lung cancers (121).  PTEN encodes a protein that has 
sequence homology with phosphatases that dephosphorylate serine/threonine and tyrosine 
residues (122, 123). Specifically, PTEN dephosphorylates PIP3 to PIP2 which limits AKT ability. 
AKT has been demonstrated as one of the important downstream targets of PI3K (124), and IKK 
is one of the downstream targets of activated AKT (100). In addition, IKK is an upstream gene in 
the NF-B pathway. AKT-mediated effects on target gene transcription lead to various cellular 
responses of cancers (121). However, it is unknown whether miRNAs acting through PTEN play 
any role in bovine lung inflammation and whether such an effect is mediated through the NF-B 
pathway. In this study, we demonstrated that PTEN is a target of miR-26b. Additionally, we 
found that NF-B signaling is up-regulated by PTEN silencing, which results in the enhancement 
of inflammatory cytokine mRNA expression levels including IL-6. IL-6 was increased by PTEN 
shRNA but it was decrease by miR-26. It indicates that IL-6 is a direct target of miR-26b. 
Moreover, under PTEN inhibition, the peak times of IL-8 and IL-10 shifted to 36 h compared 
with 1 and 6 h with miR-26b overexpression. This leaves us an interesting direction to study in 
the future. 
 In summary, our study has revealed intensive cytokine and NO responses in bAM in vitro 
to the stimulation of LPS from E. coli. In addition, a new LPS-responsive miRNA, miR-26b, in 
bAMs was identified.  miR-26b enhances inflammatory responses in vitro through the promotion 
of NF-κB pathway activity by directly targeting PTEN (Fig. 8).Consequently, miR-26b has a 
significant mechanistic role in NF-B activation in bAMs and may contribute to the 
inflammatory reaction that is important in the development of bovine lung diseases caused by 
gram-negative bacteria. Therefore, strategies aimed at mitigating miR-26b expression to reduce 
NF-B activation in bAMs may represent a potential therapy for ameliorating disease in BRD. 
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For further study, to investigate whether miR-26b is a lung specific LPS-responsive 
miRNA, the miRNA expression profile in other organs can be detected after LPS stimulation. 
Furthermore, we can detect whether the levels of miR-26b at different time points paralleled by 
the same time points showing mRNA and protein levels of PTEN to provide more evidence for 
the correlation of miR-26b and PTEN. 
IV-2:   MicroRNA-29a Efficiently Promotes the Differentiation of Mouse Induced       
           Pluripotent Stem Cells and Mesenchymal Stem Cells into Alveolar  
           Epithelial Type II cells 
IV-2-1: iPSCs 
Cell replacement therapy requires a proper source of cells for engraftment. AEC II have 
become an attractive candidate for cell therapies of lung diseases since these cells have recently 
been identified as alveolar stem cells (125) and secrete a high level of lung surfactant in the distal 
alveoli. However, it is still a challenge to generate large quantities of pure AEC II. The conditions 
for directing iPSCs to differentiate into an alveolar epithelial lineage with homogeneity are not 
fully defined yet. In the present study, we found that miR-29a promoted the differentiation of 
mouse iPSCs into AEC II through the activation of the MAPK pathway by targeting DUSP2. 
Moreover, these iPSC-AEC II are capable of secreting lung surfactant, proliferating and trans-
differentiating into AEC I.  
 The first goal of this study was to identify the optimal conditions that efficiently promote 
mouse iPSC differentiation into AEC II. Previous studies demonstrated that iPSCs were able to 
differentiate toward lung epithelium (38, 126-128). However, the efficiency was low. In our 
study, we demonstrated that miR-29a efficiently promoted mouse iPSC differentiation into AEC 
II. miR-29 has been implicated in EMT, skeletal muscle cell and osteoblast differentiation, 
systemic sclerosis, cardiac fibrosis and lung fibrosis (129-134). miR-29 negatively regulates 
several predicted targets including collagens in nasopharyngeal carcinomas and myocardial 
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infarction-associated cardiac fibrosis (133, 135). miR-29a also regulates TGF-β1-induced 
extracellular matrix synthesis through the activation of the PI3K-AKT pathway in human lung 
fibroblasts (136). In spite of all these studies, there is still no functional study of miR-29a in lung 
epithelial differentiation. Our finding that ~88% of iPSCs can be differentiated into AEC II by 
miR-29a suggests that this pathway may be amenable for use in large scale generation of AEC II 
from patient-specific iPSCs. 
miRNA causes a rapid change in protein expression via inhibition of mRNA translation 
and stability. The ability to target different proteins can rapidly impose a dominant phenotypic 
change in cell destination. Our finding indicates that miR-29a expression is essential for iPSC 
differentiation to the lung epithelial cell lineage. Thus analysis of the regulation of mRNA targets 
of miR-29a may provide important information regarding both the iPSC gene network and factors 
whose expression is essential to efficient iPSC differentiation into lung epithelial cells. In the 
present study, we identified Dual-specificity phosphatase 2 (DUSP2) as a target of miR-29a and 
showed that DUSP2 suppression enhances differentiation of iPSCs into AEC II. DUSP-2 is a 
protein tyrosine phosphatase and belongs to the class I sub-family of DUSP proteins. It is a 
negative regulator of the mitogen-activated protein kinase (MAPK) pathway. DUSP2 de-
phosphorylates the conserved TxY motif present in the activation loop of MAPK phosphatases 
(MKPs). DUSP2 is well known to influence metabolism in the immune system. It plays an 
important role in enhancing immune and inflammatory responses that are dependent on MAPK 
signaling (103). However, the regulatory roles of DUSPs in iPSC differentiation towards lung 
epithelium are unknown.  
Cellular responses such as cell differentiation, immune responses, and cell survival to 
endogenous or exogenous stimuli are directed by MAPK signaling pathways (68, 82, 137-139). 
The MAPK signaling cascade includes three sequential phosphorylation steps involving MAPK 
kinase kinase (MAPKKK), MAPK kinase (MAPKK), and MAPK. MAPKKKs phosphorylate and 
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activate MAPKKs, which in turn phosphorylate and activate MAPKs (140). A variety of substrate 
proteins including transcription factors are phosphorylated by the activated MAPKs (140). The 
MAPK pathways are activated by diverse extracellular and intracellular regulators including 
miRNAs. Three MAPK pathways [extracellular signal-regulated kinase (ERK), c-Jun N-terminal 
kinase (JNK), and p38] have been characterized in detail. A recent study has reported that the 
activation of JNK and ERK promotes osteogenesis from mesenchymal stem cells (MSCs) by 
regulating cell shape (141). However, studies on the role of MAPK pathways associated with 
DUSP in stem cell differentiation are limited. In our study, we uncovered a novel mechanism for 
the activation of the MAPK signaling pathway by miR-29a through targeting DUSP2, which 
resulted in effective enhancement of iPSC differentiation into AEC II.  
 In summary, we identified miR-29a as a mouse AEC II enriched miRNA.  miR-29a 
effectively enhances the differentiation of iPSCs into AEC II through the activation of the MAPK 
pathway by directly targeting DUSP2. Additionally, AEC II derived from miR-29a engineered-
iPSCs are functional. Our studies represent an initial and important step towards the ultimate goal 
of cell-based therapy of COPD.        
IV-2-2: MSCs 
Chronic obstructive pulmonary disease (COPD) is a common condition primarily 
associated with cigarette smoking. Chronic exposure to cigarette smoke results in emphysema 
and pulmonary inflammation. MSCs haven been used to treat lung disease. The main observation 
of this study was that miR-29a effectively promoted the differentiation of MSCs into AEC II 
through activation of the MAPK pathway by targeting DUSP2. Furthermore, these MSC-AEC II 
secrete pulmonary surfactant, proliferate and trans-differentiate into AEC I. In addition, MSC-
AEC II are also capable of ameliorating the pulmonary damage caused by elastase. The observed 
profound protective effects of MSC-AEC II in the mouse lung identify them as a potentially 
promising therapy for emphysema.  
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Previous studies have demonstrated the ability of MSCs to differentiate into several cell 
lineages including endothelial cells, the osteogenic lineage, and the epithelial lineage (142-144). 
In this study, we attempted to identify optimal conditions that efficiently promote mouse MSC 
differentiation into AEC II. We demonstrated that miR-29a efficiently promoted mouse MSC 
differentiation into AEC II. One previous study reported that epigenetic modification improved 
the differentiation of  MSC lineage specification (145). miRNAs were also found to effectively 
differentiate MSCs into specific cell lineages. miR-128 regulates the differentiation of rat 
bone MSCs into neuron-like cells via Wnt signaling (19) . Up-regulation of miR-29a strongly 
inhibits chondrocyte-specific markers during in vitro chondrogenic differentiation of MSCs by 
targeting FOXO3A (18). In spite of all these studies, there are no studies on miRNAs as they 
relate to  MSC differentiation into AEC II. Our finding that efficient differentiation of MSCs into 
AEC II is enhanced by miR-29a may prove to be amenable for use in large scale AEC II 
generation. 
Phosphorylation-dephosphorylation plays an essential role in the assembly and 
disassembly of multiprotein complexes and determines cell fate. The mitogen-activated protein 
kinase (MAPK) pathway is known to activate a wide range of transcription factors involved in 
innate immunity, cell growth, stress responses, apoptosis, and differentiation (146). The signaling 
mediators of MAPK include extracellular signal-regulated kinases (ERKs), c-Jun N-terminal 
kinases (JNKs), and p38 MAPK (147). Notably the activation of JNK and ERK1/2 MAPK are 
important in the differentiation of mouse embryonic stem cells (ESCs) and rat dental follicle stem 
cells (148, 149). miRNAs have been reported to activate MAPK through targeting upstream or 
downstream regulatory proteins. miR-21 has been reported to promote proliferation and 
migration, and to inhibit apoptosis, in Eca109 cells by activating the ERK1/2 MAPK pathway 
(150). Furthermore, miR-21 has also been demonstrated to modulate the ERK–MAPK signaling 
pathway by regulating SPRY2 expression during human mesenchymal stem cell differentiation 
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(151).  Our present study showed that the activation or inhibition of ERK or JNK signaling 
resulted in an increase or decrease of MSC-to-AEC II differentiation, pointing to the importance 
of MAPK signaling in this process.  
The ability of miRNAs to simultaneously target many mRNAs involved in cellular 
signaling increases the complexity underlying the mechanisms of miRNA actions. Correlative 
analysis of changed signaling pathways and mRNA targets of miR-29a underscores the role of 
DUSP2 in MSC-to-AEC II differentiation. The miR-29a-mediated reduction of DUSP2 protein is 
likely responsible for enhancing MSC-to-AEC II differentiation. DUSP2 is a protein tyrosine 
phosphatase that inhibits MAPK pathways. DUSP2 serves as mitogen- and stress-inducible 
nuclear MAPK phosphatase (103). However, whether DUSP2 is involved in MSC-to-AEC II 
differentiation remains unclear. In this study, we demonstrated that DUSP2 was a target of miR-
29a and miR-29a-mediated DUSP2 suppression resulted in the enhancement of the differentiation 
of MSCs into AEC II.  
Remarkably, our current studies demonstrated that MSC–AEC II are functional. First, 
MSC–AEC II are able to secrete SP-C and PC after stimulation. Second, MSC-AEC II can 
proliferate and trans-differentiate into AEC I.  This ability of MSC-AEC II cells to behave like 
native AEC II increases their potential to protect the lung from the damage caused by elastase. A 
previous study has demonstrated that adipose stem cell (ASC) can attenuate the pulmonary 
damage such as airspace enlargement and lung inflammation, and reverse body weight loss 
caused by elastase in an emphysema mouse model (65). Our MSC–AEC II are also capable of 
attenuating elastase-induced lung inflammation and airspace enlargement. The protective effects 
of MSC-AEC II in the mouse lung of elastase model suggest a potentially promising intervention 
for emphysema.  
Future studies include investigation of multiple mechanisms engaged in the therapeutic 
effects of MSC-AEC II in lung diseases, such as secretion of antiapoptotic factors, paracrine 
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protective action on neighboring resident lung cells, activation of endogenous progenitor cell 
cycling and differentiation, repair of the lung endothelial barrier, and rescue and recruitment of 
circulating cells for pulmonary repair in vivo.  
In summary, miR-29a effectively enhances MSC differentiation into AEC II in vitro 
through the activation of the MAPK pathway by directly targeting DUSP2. miR-29a engineered 
MSC-AEC II are able to secrete lung surfactant, proliferate and trans-differentiate into AEC I. 
Furthermore, miR-29a engineered MSC-AEC II exerts protective effects against elastase-induced 
airway enlargement and pulmonary inflammation. miR-29a engineered MSC-AEC II may be a 
viable therapeutic option for cell therapy of COPD.  
For future deeper study, to calculate how many miR-29a-MSC-AEC II cells could be 
delivered in vivo, the miR-29a-MSC-AEC II cells can be labeled with a fluorescent cell tracker 
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